William Jeffery Sandborn
#53,299
Most Influential Person Now
Researcher
William Jeffery Sandborn's AcademicInfluence.com Rankings
William Jeffery Sandbornengineering Degrees
Engineering
#884
World Rank
#1376
Historical Rank
#371
USA Rank
Biomedical Engineering
#5
World Rank
#5
Historical Rank
#4
USA Rank
Applied Physics
#40
World Rank
#42
Historical Rank
#19
USA Rank
William Jeffery Sandbornbiology Degrees
Biology
#1677
World Rank
#2741
Historical Rank
#809
USA Rank
Biotechnology
#7
World Rank
#7
Historical Rank
#4
USA Rank
Download Badge
Engineering Biology
William Jeffery Sandborn's Degrees
- PhD Biomedical Engineering Stanford University
Why Is William Jeffery Sandborn Influential?
(Suggest an Edit or Addition)William Jeffery Sandborn's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Infliximab for induction and maintenance therapy for ulcerative colitis. (2005) (2903)
- Infliximab, azathioprine, or combination therapy for Crohn's disease. (2010) (2727)
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (2007) (2091)
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) (1847)
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) (1815)
- Inflammatory bowel disease: clinical aspects and established and evolving therapies (2007) (1711)
- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. (2006) (1610)
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target (2015) (1329)
- A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (2000) (1189)
- The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (2001) (1113)
- A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. (2007) (1076)
- Crohn's disease (2012) (1040)
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) (1026)
- Maintenance therapy with certolizumab pegol for Crohn's disease. (2007) (1001)
- Risk factors for opportunistic infections in patients with inflammatory bowel disease. (2008) (969)
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) (945)
- Management of Crohn's Disease in Adults (2001) (939)
- The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (2002) (939)
- The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (2004) (937)
- Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. (2001) (923)
- Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. (2006) (887)
- Natalizumab induction and maintenance therapy for Crohn's disease. (2005) (887)
- The Natural History of Adult Crohn's Disease in Population-Based Cohorts (2010) (823)
- Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011) (803)
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial (2007) (792)
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011) (792)
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) (744)
- A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. (2008) (721)
- Anti-interleukin-12 antibody for active Crohn's disease. (2004) (721)
- Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. (2012) (693)
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012) (677)
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry (2012) (677)
- PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis (2004) (667)
- Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. (1994) (662)
- Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 (2007) (652)
- A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. (2002) (651)
- Certolizumab pegol for the treatment of Crohn's disease. (2007) (642)
- Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. (2014) (621)
- Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. (1998) (621)
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) (611)
- Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. (2007) (602)
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis (2011) (577)
- AGA technical review on perianal Crohn's disease. (2003) (574)
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) (573)
- Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. (2010) (570)
- Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. (2008) (559)
- A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. (2001) (558)
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial (2017) (549)
- Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease (2005) (549)
- Ulcerative colitis (2012) (546)
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020) (529)
- An Update on the Epidemiology of Inflammatory Bowel Disease in Asia (2008) (528)
- Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. (1996) (514)
- Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
- Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival (2000) (508)
- Infliximab for the treatment of fistulas in patients with Crohn'S disease. (1999) (504)
- Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. (2012) (503)
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease (2010) (490)
- Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. (1999) (486)
- A gp130–Src–YAP module links inflammation to epithelial regeneration (2015) (483)
- Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. (2006) (483)
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007) (479)
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2019) (472)
- Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. (2009) (464)
- The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review (2002) (442)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (440)
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011) (435)
- Epidemiology of inflammatory bowel disease. (2002) (434)
- Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study (2001) (432)
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis (2015) (415)
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial (2013) (404)
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial (2014) (391)
- Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. (2008) (375)
- Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. (2008) (374)
- Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. (2006) (372)
- Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy (2004) (370)
- Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. (2009) (369)
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. (2017) (367)
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review (2011) (362)
- Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial (2008) (356)
- Pouchitis following heal pouch-anal anastomosis: Definition, pathogenesis, and treatment (1994) (353)
- Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. (2007) (353)
- Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. (1999) (353)
- Crohn's disease complicated by strictures: a systematic review (2013) (350)
- Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation (2003) (350)
- Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. (2007) (338)
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial (2015) (338)
- Venous Thromboembolism in Inflammatory Bowel Disease (2004) (336)
- Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. (2010) (333)
- Reliability and initial validation of the ulcerative colitis endoscopic index of severity. (2013) (332)
- Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. (2003) (326)
- Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. (2006) (325)
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (2017) (318)
- Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. (2003) (316)
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. (2016) (315)
- Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. (2007) (312)
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients (2000) (308)
- Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial (2005) (299)
- An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease (2004) (296)
- Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. (2014) (294)
- An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease (2011) (291)
- Integrin-based therapeutics: biological basis, clinical use and new drugs (2016) (290)
- A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. (1996) (289)
- Management of Crohn's disease in adults (2001) (287)
- Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health (2011) (278)
- Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease (2005) (278)
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. (2016) (276)
- Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. (2007) (275)
- Treat to target: a proposed new paradigm for the management of Crohn's disease. (2015) (274)
- Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. (2008) (271)
- Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. (2002) (263)
- A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. (2014) (252)
- Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis (1997) (251)
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium (2016) (250)
- The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota (2006) (249)
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017) (248)
- Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. (2015) (247)
- Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. (1999) (247)
- Surgery in a Population-Based Cohort of Crohn's Disease From Olmsted County, Minnesota (1970–2004) (2012) (244)
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease (2001) (244)
- Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review (2017) (243)
- Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study (2013) (242)
- Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. (2000) (242)
- An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. (2001) (242)
- Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double‐blind, placebo‐controlled pilot study (2009) (241)
- Application of Artificial Intelligence to Gastroenterology and Hepatology. (2019) (240)
- Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein (2006) (238)
- Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. (1994) (236)
- Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. (2012) (235)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics (2011) (230)
- Development and validation of a histological index for UC (2015) (229)
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. (2019) (227)
- American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. (2007) (226)
- The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis (2003) (221)
- Adalimumab induces deep remission in patients with Crohn's disease. (2014) (221)
- Inhibition of Interleukin-1-stimulated NF-κB RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity* (1999) (220)
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data (2010) (219)
- Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes (2017) (219)
- Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease (2006) (219)
- 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy (2012) (217)
- Global chemical effects of the microbiome include new bile-acid conjugations (2020) (215)
- Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. (2016) (212)
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease (2014) (212)
- Infliximab in the treatment of Crohn's disease: a user's guide for clinicians (2002) (212)
- Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004 (2006) (210)
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease (2012) (208)
- Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. (2006) (208)
- Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies (2012) (207)
- A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. (2008) (206)
- Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Patients with Inflammatory Bowel Disease (2008) (202)
- Diagnosis and Treatment of Perianal Fistulas in Crohn Disease (2001) (201)
- Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. (2012) (199)
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials (2009) (199)
- Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. (2014) (199)
- Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide (2001) (199)
- A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease (1995) (196)
- Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease (2015) (196)
- Long‐term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population‐based cohorts (2011) (191)
- The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. (2013) (190)
- Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease (2009) (190)
- Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation (1998) (189)
- Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. (2015) (188)
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study (2014) (187)
- Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis (2018) (185)
- Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy (2000) (185)
- Biologic therapy of inflammatory bowel disease. (2002) (184)
- Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. (2006) (183)
- Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis (2008) (182)
- A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine (2005) (181)
- Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. (2014) (180)
- A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. (2013) (175)
- Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis (2018) (174)
- Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. (2002) (171)
- Inflammatory bowel disease in the setting of autoimmune pancreatitis (2009) (171)
- The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients (2007) (170)
- Indeterminate colitis: A review of the concept — What's in a name? (2008) (170)
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry (2014) (170)
- Long-term Efficacy of Vedolizumab for Ulcerative Colitis (2016) (168)
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. (2019) (167)
- Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians (2019) (165)
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
- Long-term Efficacy of Vedolizumab for Crohn’s Disease (2016) (164)
- Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse (2015) (163)
- Evaluation of Serologic Disease Markers in a Population-Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease (2001) (162)
- Management of Crohn's disease of the ileoanal pouch with infliximab (2003) (160)
- MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials (2007) (159)
- Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study (2013) (159)
- Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine (1998) (158)
- Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. (2012) (158)
- Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. (2013) (157)
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis (2015) (157)
- Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. (2007) (156)
- Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. (2009) (155)
- Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. (2018) (154)
- Epidemiology of Inflammatory Bowel Disease in Asia (2001) (154)
- Review article: biological activity markers in inflammatory bowel disease (2006) (153)
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. (2018) (151)
- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. (2020) (150)
- Microscopic colitis: a review (2002) (149)
- Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. (2013) (149)
- Lymphocytic Colitis: clinical features, treatment, and outcomes (2002) (148)
- Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. (2010) (147)
- Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case–Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota (2007) (143)
- An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. (1995) (142)
- CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial (2004) (142)
- Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. (2001) (142)
- The fate of low grade dysplasia in ulcerative colitis (2002) (142)
- Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease: A Case–Control Study (2004) (141)
- Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. (2011) (141)
- Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. (1996) (138)
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy (2017) (138)
- Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 (2014) (137)
- Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. (1999) (136)
- Incidence and Prognosis of Colorectal Dysplasia in Inflammatory Bowel Disease: A Population‐based Study from Olmsted County, Minnesota (2006) (136)
- A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. (1994) (135)
- European evidence-based consensus on the diagnosis and management of Crohn’s disease (2007) (134)
- Rational dosing of azathioprine and 6-mercaptopurine (2001) (133)
- Renal and Urologic Complications of Inflammatory Bowel Disease (1998) (132)
- Open‐label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab (2009) (132)
- Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography (2008) (131)
- Successful management of Crohn's disease of the ileoanal pouch with infliximab. (1999) (131)
- Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. (1995) (131)
- Abatacept for Crohn's disease and ulcerative colitis. (2012) (130)
- A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity (2015) (130)
- Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. (1996) (129)
- Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. (1997) (129)
- Risk of lymphoma in inflammatory bowel disease. (2000) (129)
- Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. (1996) (128)
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease (2012) (127)
- Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. (2013) (127)
- 751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy (2009) (126)
- Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease (2015) (126)
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial (2017) (126)
- Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines (2005) (124)
- Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change (2011) (124)
- Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications (2002) (123)
- Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. (2014) (123)
- A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis (2006) (122)
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (2020) (122)
- Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis (2012) (122)
- Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. (2014) (122)
- Adalimumab safety in global clinical trials of patients with Crohn's disease (2009) (122)
- Crohn’s Disease of the Esophagus: Clinical Features and Outcomes (2001) (121)
- A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. (2007) (121)
- Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. (2018) (121)
- An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease (2018) (120)
- Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease (2017) (119)
- Demyelination During Anti-Tumor Necrosis Factor &agr; Therapy With Infliximab for Crohn's Disease (2004) (117)
- Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials (2005) (117)
- Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis (2013) (117)
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. (2020) (116)
- Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis (2018) (116)
- Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease (2018) (116)
- Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. (1995) (115)
- Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. (2010) (115)
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. (2016) (114)
- Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission (2007) (113)
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. (2020) (113)
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme (2019) (113)
- Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management (2016) (113)
- Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. (2018) (113)
- Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. (2014) (112)
- Systematic review: the management of pouchitis (2006) (112)
- Current directions in IBD therapy: what goals are feasible with biological modifiers? (2008) (112)
- Crohn's disease: beyond antagonists of tumour necrosis factor (2008) (111)
- Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. (2019) (109)
- Diagnosis and management of pouchitis. (2003) (109)
- Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. (2018) (109)
- Acute major gastrointestinal hemorrhage in inflammatory bowel disease. (1999) (108)
- Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy (2018) (108)
- Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. (2020) (108)
- Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease (2008) (107)
- Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort (2015) (107)
- Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial (2003) (106)
- Adalimumab for the treatment of fistulas in patients with Crohn’s disease (2009) (106)
- Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (105)
- 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants (2013) (105)
- Short CDAI: Development and validation of a shortened and simplified Crohn's disease activity index (2011) (103)
- Symptomatic overlap between irritable bowel syndrome and microscopic colitis. (2011) (103)
- Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy (2010) (101)
- Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low‐Grade Dysplasia: A Systematic Review and Meta‐analysis (2017) (101)
- Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD (2014) (101)
- Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices (2014) (100)
- Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease (2009) (100)
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. (2019) (100)
- Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. (2010) (100)
- Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials (2015) (99)
- Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. (2017) (99)
- Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis (2007) (99)
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease (2010) (99)
- Rifaximin for the treatment of active pouchitis: A randomized, double‐blind, placebo‐controlled pilot study (2007) (98)
- Perioperative Anti-Tumor Necrosis Factor Therapy Does Not Increase the Rate of Early Postoperative Complications in Crohn’s Disease (2010) (98)
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. (2021) (98)
- A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. (2015) (98)
- Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE (2013) (98)
- Systematic review: the effectiveness of budesonide therapy for Crohn's disease (2002) (97)
- Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. (2003) (97)
- P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (2008) (96)
- Azathioprine: state of the art in inflammatory bowel disease. (1998) (96)
- Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection (1994) (96)
- IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (2019) (96)
- Early Crohn disease: a proposed definition for use in disease-modification trials (2010) (95)
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies (2016) (95)
- Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. (2016) (94)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety (2011) (94)
- Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease. (2020) (94)
- Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. (2019) (94)
- Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis (1999) (93)
- Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives (2014) (93)
- Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin (2003) (93)
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease (2014) (92)
- Internet use by patients in an inflammatory bowel disease specialty clinic (2007) (92)
- Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process (2012) (92)
- Development of an index to define overall disease severity in IBD (2016) (92)
- Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis (2009) (91)
- Pediatric “PSC-IBD”: A Descriptive Report of Associated Inflammatory Bowel Disease Among Pediatric Patients With PSC (2001) (91)
- Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. (2014) (90)
- Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. (1996) (90)
- Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health (2010) (89)
- Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial (2009) (89)
- CT enterography and fistulizing Crohn’s disease: clinical benefit and radiographic findings (2009) (89)
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. (2020) (89)
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial (2021) (87)
- Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. (2015) (87)
- State of the Art: Ibd Therapy and Clinical Trials in Ibd (2005) (86)
- Risk of lymphoma in inflammatory bowel disease (2000) (86)
- Crohn's disease evaluation and treatment: clinical decision tool. (2014) (85)
- Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results (1999) (85)
- Strategies for targeting tumour necrosis factor in IBD. (2003) (85)
- Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis (2020) (84)
- Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. (1993) (84)
- Histologic scoring indices for evaluation of disease activity in Crohn's disease. (2016) (82)
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest (2017) (82)
- Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. (2011) (82)
- P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm (2007) (81)
- Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis (2010) (81)
- Kirsner's inflammatory bowel disease (2004) (81)
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study (2018) (80)
- Serologic markers in inflammatory bowel disease: state of the art. (2004) (80)
- Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab Infusion (2002) (80)
- Erratum: Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival (Gastroenterology (1998) 114 (1161- 1168)) (1999) (80)
- Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial (2005) (80)
- Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. (2012) (78)
- New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. (2005) (78)
- Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics (2011) (77)
- Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. (2018) (77)
- Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. (1996) (77)
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists (2019) (75)
- Methylation Status of Genes in Non-Neoplastic Mucosa From Patients With Ulcerative Colitis-Associated Colorectal Cancer (2010) (75)
- Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses (2020) (75)
- Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience (2018) (75)
- Infliximab for the Treatment of Orofacial Crohn's Disease (2001) (75)
- Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study (2017) (74)
- Factors associated with short- and long-term outcomes of therapy for Crohn's disease. (2015) (74)
- Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. (2014) (74)
- A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research (2014) (74)
- Assessment of mucosal healing in inflammatory bowel disease: review. (2015) (73)
- Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. (1997) (73)
- Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers (2009) (73)
- Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease (2015) (72)
- Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trial (1997) (71)
- Pneumocystis carinii Pneumonia During Maintenance Anti–Tumor Necrosis Factor-&agr; Therapy with Infliximab for Crohn’s Disease (2004) (71)
- Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease (2002) (71)
- A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human anti body to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease (2000) (71)
- The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? (2018) (70)
- Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial (2015) (70)
- Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: A Robust yet Changing Relationship (2013) (70)
- Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects (2001) (70)
- Interactions between chronic liver disease and inflammatory bowel disease. (1997) (70)
- Reproducibility of histological assessments of disease activity in UC (2014) (69)
- Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. (2020) (69)
- Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis (2014) (69)
- Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease (2004) (69)
- Nicotine tartrate liquid enemas for mildly to moderately active left‐sided ulcerative colitis unresponsive to first‐line therapy: a pilot study (1997) (68)
- Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease (2009) (68)
- A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease (2004) (68)
- A phase II study of laquinimod in Crohn's disease (2014) (68)
- Outcome of Sporadic Adenomas and Adenoma‐Like Dysplasia in Patients with Ulcerative Colitis Undergoing Polypectomy§† (2012) (68)
- Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies (2015) (68)
- Advances in the treatment of Crohn's disease. (2004) (68)
- Symptomatic overlap between irritable bowel syndrome and microscopic colitis (2007) (68)
- Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: A case–control study (2009) (67)
- Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis (2001) (67)
- Biologic Concentration Testing in Inflammatory Bowel Disease (2015) (67)
- Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease (2018) (67)
- A comparison of budesonide and mesalamine for active Crohn's disease. (1999) (67)
- Review article: dose optimisation of infliximab for acute severe ulcerative colitis (2017) (67)
- Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. (1995) (67)
- Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis (1998) (67)
- Cyclosporine treatment of inflammatory bowel disease. (1992) (66)
- Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial (2005) (66)
- Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis (2015) (66)
- Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. (2010) (65)
- Nicotine enemas for active ulcerative colitis—a pilot study (1997) (65)
- Benefit of Computed Tomography Enterography in Crohn's Disease: Effects on Patient Management and Physician Level of Confidence§† (2012) (65)
- Clinical management of pouchitis. (2004) (64)
- Update on Janus kinase antagonists in inflammatory bowel disease. (2014) (64)
- Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. (2003) (64)
- Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. (2006) (64)
- Biologics in inflammatory bowel disease: how much progress have we made? (2004) (63)
- Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis (2015) (63)
- Mild to moderate Crohn's disease – defining the basis for a new treatment algorithm (2003) (63)
- Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease (2020) (63)
- 751e Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease – First Results of the Extend Trial (2009) (62)
- Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study (2013) (62)
- Erythrocyte Mean Corpuscular Volume as a Surrogate Marker for 6-Thioguanine Nucleotide Concentration Monitoring in Patients with Inflammatory Bowel Disease Treated with Azathioprine or 6-Mercaptopurine (2003) (61)
- Post Hoc Analysis (2022) (61)
- Tumor Necrosis Factor-Alpha Polymorphisms in Ulcerative Colitis-Associated Colorectal Cancer (2008) (60)
- Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. (1999) (60)
- Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. (1993) (60)
- Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation (2016) (60)
- Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. (1999) (60)
- Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease (2014) (59)
- MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations (2008) (59)
- Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials (2018) (59)
- Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts. (2020) (59)
- Population Health Management for Inflammatory Bowel Disease. (2018) (59)
- Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel (2011) (58)
- Cost‐Effectiveness of Imaging Strategies to Reduce Radiation‐Induced Cancer Risk in Crohn's Disease (2012) (58)
- Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis (2011) (57)
- Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? (2019) (57)
- Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab (2016) (57)
- The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. (2004) (57)
- Concurrent inflammatory bowel disease and myelodysplastic syndromes. (1998) (57)
- Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. (2012) (56)
- Introducing vedolizumab to clinical practice: who, when, and how? (2015) (55)
- Acute Pancreatitis in Patients With Crohn's Disease: Clinical Features and Outcomes (2005) (55)
- Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. (2018) (55)
- Preliminary data on the use of apheresis in inflammatory bowel disease (2006) (55)
- Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. (2020) (55)
- Long‐term safety of vedolizumab for inflammatory bowel disease (2020) (55)
- Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. (2012) (55)
- Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease (2018) (55)
- Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. (2002) (55)
- Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis† (2010) (54)
- Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. (2020) (54)
- Biosimilars in IBD: hope or expectation? (2013) (54)
- Symptomatic Overlap Between Microscopic Colitis and Irritable Bowel Syndrome: A Prospective Study (2013) (54)
- Myeloperoxidase Immunohistochemistry as a Measure of Disease Activity in Ulcerative Colitis: Association With Ulcerative Colitis‐Colorectal Cancer, Tumor Necrosis Factor Polymorphism and RUNX3 Methylation (2011) (54)
- Pharmacotherapy for inducing and maintaining remission in pouchitis. (1998) (54)
- Cyclosporin for refractory ulcerative colitis (2003) (53)
- Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open (2019) (53)
- Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death (2018) (53)
- A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease: Recommendations for Clinical Trial Design (2014) (53)
- Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? (2005) (53)
- Strategies for the care of adults hospitalized for active ulcerative colitis. (2012) (53)
- Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease (2005) (53)
- The effectiveness of budesonide therapy for Crohn's disease. (2002) (52)
- Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients (2010) (51)
- Colectomy and the Incidence of Postsurgical Complications Among Ulcerative Colitis Patients With Private Health Insurance in the United States (2008) (51)
- Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. (2019) (51)
- Is antibody testing for inflammatory bowel disease clinically useful? (1999) (51)
- Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. (2012) (50)
- Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease (2007) (50)
- Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. (2016) (50)
- Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. (2017) (50)
- Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis (2002) (50)
- DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS. (2019) (50)
- Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial (2017) (50)
- Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program (2020) (49)
- Measurement of disease activity in ulcerative colitis: Interobserver agreement and predictors of severity (2011) (49)
- Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. (2019) (49)
- Evolving Definitions of Remission in Crohn’s Disease (2013) (49)
- Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. (2019) (49)
- Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease (2017) (49)
- Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. (2018) (49)
- Oral Nicotine in Treatment of Primary Sclerosing Cholangitis (A Pilot Study) (2004) (49)
- Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. (2016) (48)
- Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis (2016) (47)
- Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open‐label pilot study (2009) (47)
- CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial (2006) (47)
- The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] (2015) (47)
- Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis (2017) (47)
- Pregnancy Outcomes Reported During the 13‐Year TREAT Registry: A Descriptive Report (2018) (47)
- Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. (2019) (47)
- Annual Burden and Costs of Hospitalization for High‐Need, High‐Cost Patients With Chronic Gastrointestinal and Liver Diseases (2018) (46)
- Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy (2016) (46)
- Prevalence of Fistulizing Crohn’s Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis (2019) (46)
- 499 The Effect of Maternal Peripartum Infliximab Use On Neonatal Immune Response (2008) (46)
- Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease (2003) (46)
- Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease (2010) (46)
- Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions (2015) (46)
- High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis (2018) (46)
- Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial (2018) (46)
- Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience (2012) (46)
- Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. (2017) (45)
- Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis (1995) (45)
- Ustekinumab for Peristomal Pyoderma Gangrenosum (2012) (45)
- Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease (2015) (45)
- Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice (2006) (45)
- Lymphoma of the pouch after ileal pouch-anal anastomosis (1997) (45)
- Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with Crohn's Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study (2013) (44)
- N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis (2002) (44)
- The Pharmacokinetics and Colonic Tissue Concentrations of Cyclosporine After IV, Oral, and Enema Administration (1991) (44)
- Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis (2012) (44)
- Deep Remission: A New Concept? (2013) (44)
- Assessment of appropriateness of indications for CT enterography in younger patients (2010) (43)
- Age at onset of inflammatory bowel disease and the risk of surgery for non‐neoplastic bowel disease (2007) (43)
- O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFN&agr;: UNITI-1 (2016) (43)
- The relationship between in fl iximab concentrations , antibodies to in fl iximab and disease activity in Crohn ’ s disease (2014) (43)
- Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. (2019) (43)
- Reliability of histologic assessment in patients with eosinophilic oesophagitis (2018) (43)
- Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease (2008) (43)
- Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. (2018) (43)
- 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) (2012) (42)
- State-of-the-Art: Immunosuppression and Biologic Therapy (2010) (42)
- Design Issues and Outcomes in Ibd Clinical Trials (2005) (42)
- Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. (2019) (42)
- 960 Exposure to Anti-TNFα Therapy in the Third Trimester of Pregnancy Is Not Associated With Increased Adverse Outcomes: Results From the PIANO Registry (2014) (42)
- 566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis (2012) (42)
- Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. (2012) (42)
- Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing: A Post hoc Analysis from SONIC (2015) (42)
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies (2020) (42)
- Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial. (2021) (42)
- The Natural History of Surgery for Ulcerative Colitis in a Population-Based Cohort from Olmsted County, Minnesota: 819 (2005) (41)
- Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease (1999) (41)
- Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases (2019) (41)
- Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review (2018) (41)
- Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. (2019) (41)
- Multi-omics analyses of the Ulcerative Colitis gut microbiome link Bacteroides vulgatus proteases with disease severity (2021) (41)
- Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. (2018) (41)
- Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. (2002) (41)
- Assessment of Histologic Disease Activity in Crohn's Disease: A Systematic Review (2014) (40)
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. (2021) (40)
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials (2022) (40)
- Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey (2017) (39)
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (2022) (39)
- Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. (1998) (39)
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme (2020) (39)
- The development of a magnetic resonance imaging index for fistulising Crohn's disease (2017) (39)
- Innovations in Oral Therapies for Inflammatory Bowel Disease (2019) (39)
- No Benefit of Concomitant 5‐Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials (2018) (39)
- Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials (2019) (39)
- Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. (2001) (39)
- 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial (2012) (38)
- Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads (2019) (38)
- Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis (2017) (38)
- Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases. (2019) (38)
- Pouchitis Is Associated with Mucosal Imbalance Between Interleukin‐8 and Interleukin‐10 (2000) (38)
- Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009 (2013) (37)
- Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (37)
- Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (2018) (37)
- The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here? (2013) (37)
- 1 Achievement of Developmental Milestones Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry (2014) (37)
- Perianal Crohn's disease findings other than fistulas in a population‐based cohort (2012) (37)
- Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. (2018) (37)
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. (2018) (37)
- Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. (2004) (37)
- Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. (2015) (37)
- Development and Validation a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. (2019) (36)
- Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment (2021) (36)
- Medical Therapy for Induction and Maintenance of Remission in Pouchitis: A Systematic Review (1999) (36)
- Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease (2006) (36)
- Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease (2020) (36)
- Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease (2017) (36)
- Mucosal healing in inflammatory bowel disease. (2008) (36)
- Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2019) (36)
- Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease (2017) (35)
- Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue (1995) (35)
- Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection (1992) (35)
- Oral 5-ASA Therapy in Ulcerative Colitis: What are the Implications of the New Formulations? (2008) (35)
- Frailty is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. (2020) (35)
- The Present and Future of Inflammatory Bowel Disease Treatment. (2016) (35)
- Development of Clinical Prediction Models for Surgery and Complications in Crohn’s Disease (2018) (35)
- Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis (2019) (35)
- Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient (2018) (34)
- Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. (2019) (34)
- Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year (2016) (34)
- 437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry (2016) (34)
- Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study (2021) (34)
- Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis (2020) (34)
- A prospective cohort study of practice guidelines in inflammatory bowel disease (2001) (34)
- Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. (2016) (34)
- Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis (2018) (34)
- Challenges in IBD Research: Update on Progress and Prioritization of the CCFA's Research Agenda (2013) (34)
- Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease (2011) (33)
- Positioning biologic therapy for Crohn’s disease and ulcerative colitis (2007) (33)
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial (2022) (33)
- Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy: Results of the GAIN Study (2006) (33)
- Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. (2022) (33)
- A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis (2020) (32)
- Intravenous azathioprine in severe ulcerative colitis: a pilot study (2000) (32)
- Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial (2016) (32)
- Pharmacokinetics of Nicotine Tartrate after Single‐Dose Liquid Enema, Oral, and Intravenous Administration (1997) (32)
- Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis (2017) (32)
- Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. (2016) (32)
- Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. (2000) (32)
- T1193 A Randomized, Double-Blind, Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis (2009) (32)
- Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. (2021) (32)
- A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study (2003) (32)
- Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. (2018) (32)
- Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set (2017) (32)
- Successful Use of Infliximab in the Treatment of Corticosteroid Dependent Collagenous Colitis (2013) (32)
- Host engulfment pathway controls inflammation in inflammatory bowel disease (2020) (32)
- Fistulas to the urinary system in Crohn's disease: clinical features and outcomes (2002) (31)
- Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. (1999) (31)
- Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis (2015) (31)
- Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. (2002) (31)
- Positioning Therapies in the Management of Crohn's Disease. (2020) (31)
- Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Haploinsufficiency (2015) (30)
- Pharmacogenomics and IBD: TPMT and Thiopurines (2004) (30)
- 825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study (2015) (30)
- Cyclosporine in ulcerative colitis: state of the art. (2001) (30)
- An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. (2021) (30)
- Safety of Infliximab and Other Crohnʼs Disease Therapies: Treat™ Registry Data with 24,575 Patient-Years of Follow-up (2008) (29)
- OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study (2021) (29)
- Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease (2017) (29)
- Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (2021) (29)
- MHC Class II alleles in ulcerative colitis-associated colorectal cancer (2009) (29)
- Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials (2016) (29)
- Sa1198 Agreement Among Experts in the Endoscopic Evaluation of Postoperative Recurrence in Crohn's Disease Using the Rutgeerts Score (2014) (29)
- A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease (2005) (29)
- 901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study (2015) (29)
- Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. (2004) (29)
- Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy (2020) (29)
- Comparative pharmacokinetics of equimolar doses of 5‐aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single‐dose, crossover study in healthy volunteers 1 (2004) (29)
- 943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC (2012) (28)
- OTU-003 Etrolizumab as induction therapy in moderate to severe crohn’s disease: results from bergamot cohort 1 (2018) (28)
- Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis (1997) (28)
- Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. (2016) (28)
- A new syndrome of Crohn's disease and pachydermoperiostosis in a family. (1997) (28)
- Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease (2016) (28)
- Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease (2018) (28)
- Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis (2005) (28)
- Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial (2006) (28)
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial (2022) (28)
- Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. (2018) (28)
- Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. (2001) (28)
- Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis (2018) (28)
- Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial (2021) (28)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial (2011) (28)
- Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study (2016) (28)
- Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases (2019) (27)
- Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study (2017) (27)
- Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. (2017) (27)
- Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials (2015) (27)
- Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
- A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease (2003) (27)
- Colectomy subtypes, follow‐up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States (2009) (27)
- Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States (2016) (27)
- Transcending conventional therapies: the role of biologic and other novel therapies. (2001) (27)
- Progression of Elderly-Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-based Cohort Studies. (2020) (27)
- N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. (2002) (27)
- Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study (2021) (27)
- 494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study (2008) (27)
- Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. (2020) (26)
- Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. (2006) (26)
- Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. (2018) (26)
- Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression (2017) (26)
- US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. (2019) (25)
- Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease (2009) (25)
- Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm (2017) (25)
- Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
- Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. (2018) (25)
- A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration (1997) (25)
- CLINICAL-ALIMENTARY TRACT A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis (2007) (25)
- Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. (1996) (25)
- Risk of lymphoma in inflammatory bowel disease: A population-based estimate (1998) (24)
- Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases (2019) (24)
- Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease (2013) (24)
- Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis (2018) (24)
- Recent advances in the management of perianal fistulizing Crohn’s disease: lessons for the clinic (2019) (24)
- Higher Remission and Maintenance of Response Rates with Subcutaneous Monthly Certolizumab Pegol in Patients with Recent-Onset Crohnʼs Disease: Data from PRECiSE 2 (2006) (24)
- Early measles virus infection is associated with the development of inflammatory bowel disease (2000) (24)
- A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) (2004) (24)
- Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. (2018) (24)
- Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. (1995) (24)
- Effi cacy of Biological Therapies in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis (2011) (23)
- Definitions of response and remission for the Robarts Histopathology Index (2018) (23)
- Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease (2021) (23)
- CLASSIC-I study the efficacy of adalimumab. (2006) (23)
- Clinical pharmacology of inflammatory bowel disease therapies (2000) (23)
- The Natural History of Surgery for Crohnʼs Disease in a Population-Based Cohort from Olmsted County, Minnesota: 825 (2005) (23)
- Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies (2019) (23)
- 445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis (2015) (23)
- Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. (1999) (23)
- Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study (2020) (23)
- Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis. (2020) (23)
- Su2080 Efficacy of Budesonide MMx(r) 6 mg QD for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study (2012) (23)
- T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND (2010) (23)
- Mid Pouch Strictureplasty for Crohn’s Disease After Ileal Pouch-Anal Anastomosis: An Alternative to Pouch Excision (2004) (22)
- Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials (2018) (22)
- OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease. (2017) (22)
- Erythropoietin for inflammatory bowel disease anemia. (1997) (22)
- Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. (1998) (22)
- Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis (2011) (22)
- The appendix in ulcerative colitis: a not so innocent bystander. (1999) (22)
- Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. (2021) (22)
- DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies (2014) (22)
- 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials (2016) (22)
- Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. (2016) (22)
- Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab: Results of a Blinded, Placebo-Controlled Study (2005) (22)
- Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. (2021) (22)
- 847t Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis (2010) (22)
- How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. (2004) (22)
- Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT (2019) (22)
- Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. (2007) (22)
- Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. (1996) (21)
- Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease (2019) (21)
- Next-Generation Therapeutics for Inflammatory Bowel Disease (2016) (21)
- Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents (2010) (21)
- 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study (2018) (21)
- Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis (2020) (21)
- Evidence-based treatment algorithm for mild to moderate Crohn's disease. (2003) (21)
- Measurement of Colonic Tissue Cyclosporine Concentration in Children with Severe Ulcerative Colitis (1992) (21)
- Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. (2018) (21)
- Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis (2020) (21)
- 920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial (2008) (21)
- Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. (2010) (20)
- Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis (1998) (20)
- Microscopic colitis is not associated with cholecystectomy or appendectomy (2006) (20)
- Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. (2019) (20)
- Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis. (2020) (20)
- Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension (2018) (20)
- Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522 (2012) (20)
- Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. (2011) (20)
- T1040 Safety of Infliximab and Other Crohn's Disease Therapies: TREAT™ Registry Data With 27, 762 Patient-Years of Follow-up (2010) (20)
- Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. (2018) (20)
- Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us? (2014) (19)
- Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. (2019) (19)
- Efficient Early Drug Development for Ulcerative Colitis. (2016) (19)
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. (2021) (19)
- How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease (2016) (19)
- Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases (2020) (19)
- 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease (2019) (19)
- Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study (2013) (19)
- Outcomes of Computed Tomography and Magnetic Resonance Enterography in Clinical Practice of Inflammatory Bowel Disease (2014) (19)
- Early measles virus infection is associated with the development of inflammatory bowel disease. (2000) (19)
- Challenges in IBD Research: updating the scientific agendas. (2003) (19)
- Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study (2017) (19)
- Sa1934 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab during IV Induction and SC Maintenance Treatment of Patients with Crohn's Disease with Ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI Studies (2016) (18)
- A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials (2018) (18)
- Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease (2017) (18)
- Rate of, Risk Factors for, and Interventions to Reduce Hospital Readmission in Patients with Inflammatory Bowel Diseases. (2020) (18)
- 768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI (2016) (18)
- Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity (2020) (18)
- A case-matched study of laparoscopic proctocolectomy and ileal pouch-anal anastomosis (PC-IPAA) versus open PC-IPAA for ulcerative colitis (UC) (2001) (18)
- Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. (2018) (18)
- Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis (2016) (18)
- OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial (2014) (18)
- Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing (2020) (18)
- P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study (2018) (18)
- P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2 (2013) (18)
- A Dose‐Ranging Study of Azathioprine Pharmacokinetics After Single‐Dose Administration of a Delayed‐Release Oral Formulation (1997) (18)
- Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases (2018) (18)
- Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. (2013) (17)
- Cigarette smoking and celiac sprue: a case-control study (2001) (17)
- Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis (2017) (17)
- An evaluation of adalimumab on the risk of hospitalization in patients with Crohnʼs disease, data from CHARM: O-007. (2008) (17)
- Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. (2017) (17)
- A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease (2019) (17)
- Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease (2022) (17)
- Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial (2020) (17)
- A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. (1997) (17)
- Strategies targeting tumor necrosis factor in Crohn's disease. (2001) (17)
- OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study (2020) (16)
- Drug therapy for inflammatory bowel disease. (1998) (16)
- 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study (2021) (16)
- International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease (2021) (16)
- Acute major lower GI Hemorrhage in inflammatory bowel disease (1997) (16)
- IBD: Indication extrapolation for anti-TNF biosimilars (2015) (16)
- Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. (2020) (16)
- An Enhanced Barrier is a Better Defense: Effects of Probiotics on Intestinal Barrier Function (2002) (16)
- Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (16)
- Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation (2017) (16)
- The safety profile of infliximab for Crohn's disease in clinical practice: The Mayo clinic experience in 500 patients (2003) (16)
- Dexpanthenol enemas in ulcerative colitis: a pilot study. (1997) (16)
- Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis (2019) (16)
- Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. (2000) (16)
- Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II (2021) (16)
- S1031 Crohn's Disease Mucosal Healing in Adalimumab-Treated Patients is Affected by Disease Duration: Results From Extend (2010) (16)
- The natural history of fistulizing Crohn's disease: A population-based study (2000) (16)
- A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. (2019) (15)
- Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn’s disease: A Case Series (2018) (15)
- What's new: innovative concepts in inflammatory bowel disease (2006) (15)
- Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. (2020) (15)
- Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. (2020) (15)
- IBD: Measuring what counts—endoscopic assessment in IBD (2014) (15)
- CDP571, a humanized monoclonal antibody to TNF-α, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab (2003) (15)
- Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. (2021) (15)
- Clinical Outcome and Pharmacokinetics After Addition of Low‐Dose Cyclosporine to Methotrexate: A Case Study of Five Patients with Treatment‐Resistant Inflammatory Bowel Disease (2000) (14)
- Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. asacol and colazal (2002) (14)
- Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials. (2020) (14)
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. (2010) (14)
- Update on incidence and prevalence of Crohn's disease (CD) and ulcerative colitis (UC) in olmsted county, minnesota (2003) (14)
- 6-MP metabolite levels: a potential guide to Crohn's disease therapy. (1997) (14)
- Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis (2011) (14)
- Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. (2013) (14)
- Management of Crohn's disease in adults. (2001) (14)
- Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease (2017) (14)
- The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis (2010) (14)
- 52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants (2011) (14)
- Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases (2016) (14)
- Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With infliximab. (2020) (14)
- Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2022) (14)
- Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? (1998) (14)
- P-145 WELCOME 54-week Open-label Extension: Efficacy of Certolizumab Pegol in Crohn’s Disease Patients With Secondary Failure and Anti-Infliximab Antibodies (2013) (14)
- 812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study (2016) (14)
- Minimally Important Difference for WPAI:CD Scores: Defining Relevant Impact on Work Productivity in Active Crohnʼs Disease: 962 (2007) (14)
- 159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis (2013) (13)
- Comparative Risk of Serious Infections with Tumor Necrosis Factor-α Antagonists vs. Vedolizumab in Patients with Inflammatory Bowel Diseases. (2021) (13)
- A Randomized, Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately to Severely Active Ulcerative Colitis (2010) (13)
- Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. (2022) (13)
- Risk Factors , and Outcomes of Colorectal Cancer in Patients with Ulcerative Colitis with Low-Grade Dysplasia : A Systematic Review and Meta-analysis (2016) (13)
- New Targets for Small Molecules in Inflammatory Bowel Disease. (2015) (13)
- Other clinical studyEarly cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue (1995) (13)
- Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results. (2022) (13)
- Mucosal healing with infliximab: results from the active ulcerative colitis trials. (2012) (13)
- Henoch–Schönlein Purpura in an Adult Mimicking Crohn’s Disease and Pyoderma Gangrenosum (2011) (13)
- The Role of Psychosocial Care in Adapting to Health Care Reform. (2015) (13)
- Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. (2012) (13)
- 1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial (2014) (13)
- A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. (2005) (13)
- Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis (2013) (13)
- OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis (2018) (13)
- Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. (2020) (13)
- The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease (2018) (13)
- Steroid-dependent Crohn's disease. (2000) (13)
- Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease (2015) (12)
- Practice guidelines for inflammatory bowel disease: an instrument for assessment. (1999) (12)
- A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. (2018) (12)
- Epidemiology of inflammatory bowel disease : Epidemiology and pathogenesis of inflammatory bowel disease (2002) (12)
- OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study (2019) (12)
- Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis. (2020) (12)
- Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis (2015) (12)
- Tailoring Treatment to the Individual Patient: Drug Monitoring (2014) (12)
- OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. (2017) (12)
- Su2079 Certolizumab Pegol Plasma Concentration and Clinical Remission in Crohn's Disease (2012) (12)
- OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD) (2018) (12)
- Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis (2015) (12)
- Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies (2016) (12)
- Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. (2019) (12)
- Sustained Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease with Adalimumab, Regardless of Anti-TNF History or Concomitant Immunosuppressant Therapy: 1173 (2006) (12)
- 799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve (2019) (12)
- 11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial (2013) (12)
- Immunology and inflammation of the gastrointestinal tract:Edited by Stephen P. James and William F. Stenson. 68 pp./115 slides. $135.00. Milner-Fenwick Inc., Timonium, Maryland, 1994. American Gastroenterological Association Undergraduate Teaching Project. Slide Unit 28 (1995) (12)
- Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study (2017) (12)
- P041 THE GUT-SELECTIVE, ORALLY ADMINISTERED, PAN-JAK INHIBITOR TD-1473 DEMONSTRATES FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETIC, AND SIGNAL FOR CLINICAL ACTIVITY IN SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS (2019) (12)
- Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators: P-027. (2008) (12)
- Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? (1998) (12)
- Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases. (2021) (11)
- Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis (2022) (11)
- Estimates of the Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients with Inflammatory Bowel Diseases. (2020) (11)
- A randomized, single-blind, pharmacokinetic and doseresponse study of subcutaneous methotrexate, 15 and 25 mg/week, for refractory ulcerative colitis and Crohn's disease (1998) (11)
- P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 (2014) (11)
- Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. (2018) (11)
- Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2021) (11)
- Utility of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), anti-saccharomyces cerevisiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (2000) (11)
- Is there still a role for thiopurines in Crohn's disease? (2013) (11)
- Mycophenolate mofetil for Crohn's disease? (1999) (11)
- S1211 Clinical Benefit of CT Enterography in Suspected or Established Crohn's Disease: Impact On Patient Management and Physician Level of Confidence (2008) (11)
- PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. (2021) (11)
- Economic Impact of Deep Remission in Adalimumab-Treated Patients With Crohn's Disease: Results From Extend (2011) (11)
- Comparison of the Efficacy and Safety of SPD476, a Novel, Once-Daily, High-Dose Formulation of Mesalamine, and Asacol with Placebo for the Induction of Remission of Mild-Moderate Ulcerative Colitis: A Phase III Study (2005) (11)
- IBD in 2011: Advances in IBD management—towards a tailored approach (2012) (11)
- Nicotine carbomer enemas--pharmacokinetics of a revised formulation. (1998) (11)
- Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study (2021) (11)
- Relationships between C-reactive protein concentration and genotype in healthy volunteers (2009) (11)
- P133 Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn's disease: A meta-study (2012) (11)
- Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohnʼs Disease (CD): 1245 (2010) (11)
- DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open (2018) (11)
- The natural hisory of fistulizing Crohn's disease: A population-based study (2000) (11)
- 649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) (2010) (11)
- OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study (2014) (11)
- Mo1800 Risk Factors for Serious Infections in Elderly Patients Receiving Infliximab and Other Crohn's Disease Therapies: TREAT™Registry Data (2010) (11)
- An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials (2021) (11)
- Risk of Relapse in Patients with Ulcerative Colitis with Persistent Endoscopic Healing: A Durable Treatment Endpoint. (2020) (11)
- MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis (2009) (10)
- AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. (2008) (10)
- Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? (1998) (10)
- A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS (2019) (10)
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice (2020) (10)
- Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND: 1190 (2010) (10)
- Treatment of Crohn’s disease with certolizumab pegol (2007) (10)
- Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) (2021) (10)
- Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. (2020) (10)
- Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. (2016) (10)
- Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease≥100 points (2003) (10)
- DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. (2017) (10)
- Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. (2019) (10)
- 143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab (2009) (10)
- Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: P‐27 (2012) (10)
- Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542 (2012) (10)
- Population Pharmacokinetics and Exposure-response Modeling of Golimumab in Adults with Moderately to Severely Active Ulcerative Colitis. (2020) (10)
- OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study (2020) (10)
- 855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial (2016) (10)
- Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis (2020) (10)
- Adalimumab Improves Health-Related Quality of Life for 52 Weeks in Patients With Ulcerative Colitis (2011) (10)
- OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis (2018) (10)
- 413 Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease (2010) (10)
- Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium (2017) (10)
- 749 Infliximab for Prevention of Recurrence of Post-Surgical Crohn's Disease Following Ileocolonic Resection: A Randomized, Placebo-Controlled Study (2015) (10)
- M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial (2008) (10)
- Advances In The Comprehensive Management of Post-Operative Crohn's Disease. (2021) (10)
- Efficacy and Safety of Abrilumab (AMG 181/MEDI 7183) Therapy for Moderate to Severe Crohn’s Disease (2017) (10)
- P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders (2014) (9)
- The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review (2002) (9)
- Ileal pouch anal anastomosis and the problem of pouchitis (1997) (9)
- SPD476 Is a Novel, Once-Daily, High-Dose, Effective and Well Tolerated 5ASA Formulation for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis: A Phase III Study (2005) (9)
- Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State: 1200 (2010) (9)
- Ozanimod Treatment for Ulcerative Colitis. (2016) (9)
- How to Avoid Treating Irritable Bowel Syndrome with Biologic Therapy for Inflammatory Bowel Disease (2010) (9)
- Exposure to Biologic Therapy and Childhood Development among Offspring of Women with Inflammatory Bowel Disease: Results from the Piano Registry (2017) (9)
- Hospitalization Rates for Crohnʼs Disease Patients in Olmsted County, Minnesota, in the Pre-Biologic Era: 1004 (2007) (9)
- Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. (2020) (9)
- Step-up versus top-down therapy in the treatment of ulcerative colitis. (2007) (9)
- Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. (2011) (9)
- 702 Efficacy and Safety of Delayed-Release Oral mesalamine At 4.8g/D (800mg Tablet) in the Treatment of Moderately Active Ulcerative Colitis: Results of the Ascend III Study (2008) (9)
- Safety of Infliximab and Other Crohn's Disease Therapies: Treat™ Registry Data With a Mean of 5 Years of Follow-up (2011) (9)
- Head-to-head Comparative Studies: Challenges and Opportunities? (2016) (9)
- No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy (2020) (9)
- Pregnancy Outcomes in Patients with Crohnʼs Disease Treated with Infliximab: Results from the TREATTM Registry: 1727 (2013) (9)
- Transanal Endoscopic Surgical Proctectomy for Proctitis Case Series Report: Diversion, Radiation, Ulcerative Colitis, and Crohn’s Disease (2013) (9)
- 841 The Natural History of Microscopic Colitis Treated with Corticosteroids (2008) (9)
- Efficacy and Safety of Abrilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study (2017) (9)
- High‐Volume Postobstructive Choleresis After Transhepatic External Biliary Drainage Resolves with Conversion to Internal Drainage (1993) (9)
- Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. (1999) (9)
- Cigarette smoking and celiac sprue: a case-control study. (2001) (9)
- Developing an Ulcerative Colitis Endoscopic Index of Severity (Uceis): Results of Pilot Phase (2008) (8)
- P176 Patient reported outcome measures derived from the Crohn's Disease Activity Index: Correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds (2014) (8)
- Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study (2017) (8)
- S1184 Cumulative Incidence of and Risk Factors for Major Abdominal Surgery in a Population-Based Cohort of Crohn's Disease (2010) (8)
- Validation of Gene Expression Biomarker Analysis for Biopsy-based Clinical Trials in Crohn's Disease (2015) (8)
- P285 Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score (2014) (8)
- Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes (2019) (8)
- OP024 Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease (2014) (8)
- Obesity Is Associated with Worse Outcomes in Hospitalized Patients with Inflammatory Bowel Diseases: A Nationwide Analysis: 591 (2016) (8)
- Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review (2021) (8)
- Severe ulcerative colitis (1999) (8)
- Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohnʼs Disease: 669 (2017) (8)
- Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn’s Disease in Population-Based Cohort Studies (2021) (8)
- Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. (2019) (8)
- Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study (2020) (8)
- OP09 Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis (2019) (8)
- Therapy for Crohn disease (2000) (8)
- OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study. (2017) (8)
- Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. (2018) (8)
- Budesonide-MMx® 9 mg for Induction of Remission of Mild-to-Moderate Ulcerative Colitis (UC): Data From a Multicenter, Randomized, Double-Blind Placebo-Controlled Study in the Europe, Russia, Israel and Australia (2011) (8)
- P150 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis (2014) (8)
- Sa1761 - Efficacy and Safety of Dose Escalation to Tofacitinib 10 Mg Bid for Patients with Ulcerative Colitis Following Loss of Response on Tofacitinib 5 Mg Bid Maintenance Therapy: Results from Octave Open (2018) (8)
- Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease (2020) (7)
- THERAPY FOR ULCERATIVE COLITIS (1998) (7)
- Induction Therapy with Certolizumab Pegol in Patients with Moderate to Severe Crohnʼs Disease: A Placebo-Controlled Trial: 1156 (2010) (7)
- Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. (2020) (7)
- S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study (2010) (7)
- 764 One Year Newborn Outcomes Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry (2010) (7)
- T1153 Infliximab Treatment for Ulcerative Colitis: Comparable Clinical Response, Clinical Remission, and Mucosal Healing in Patients with Disease Duration < 3 Years Vs ≥ 3 Years (2008) (7)
- P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. (2017) (7)
- OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study (2019) (7)
- DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis (2018) (7)
- 277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (7)
- Cross-sectional study of IBD patients taking aza-thioprine (AZA) or 6-mercaptopurine (6-MP): Lack of correlation between disease activity and 6-thioguanine nucleotide (6TGN) concentration (2000) (7)
- W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years (2009) (7)
- 496 Long-Term Safety of An Anti-TNF Drug By Duration of Exposure Compared to Non-Anti-TNF Exposed Patients with Crohn's Disease: Novel Data from the Certolizumab Pegol Development Program (2008) (7)
- Evolution of Endoscopic Activity Scores in Patients With Crohn's Disease Under Azathioprine and/or Infliximab: A Post-Hoc Analysis of the Sonic Data (2011) (7)
- Active Electronic Arrays for Genotyping of NAT2 Polymorphisms (2001) (7)
- An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials (2021) (7)
- Initial combination therapy in early Crohn's disease (2008) (7)
- Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. (2019) (7)
- Response after 12 Weeks of Adalimumab Therapy in Patients with Crohnʼs Disease Who Were Nonresponders at Week 4: 966 (2008) (7)
- Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. (2021) (7)
- 906 - Efficacy and Safety of Upadacitinib Maintenance Treatment for Moderate to Severe Crohn's Disease: Results from the Celest Study (2018) (7)
- Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis. (2021) (7)
- Infliximab versus ciclosporin in severe ulcerative colitis (2012) (7)
- Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials (2019) (7)
- Sustained Steroid-Free Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease Treated with Adalimumab: 1181 (2006) (7)
- Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6”[J Crohns Colitis 8S1 (2014) P497 S274-5] (2014) (7)
- Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey (2018) (7)
- Pre-Morbid Obesity is Associated with Increased Risk of Developing Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis (2017) (7)
- Evaluation of an Interim Crohn’s Disease Outcome Measure (PRO−2) Based on 2 Patient-Reported Components (Stool Frequency, Abdominal Pain) of the Crohn’s Disease Activity Index (CDAI) in the Ustekinumab CERTIFI Study: 1679 (2014) (7)
- Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies (2019) (7)
- S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study (2020) (7)
- Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease (2021) (7)
- Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. (2009) (7)
- Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study (2016) (7)
- OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study (2018) (7)
- Budesonide Mxx® 9 mg for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis (UC): Data From a Multicenter, Randomized, Double-Blind Placebo-Controlled Study in North America and India (2011) (7)
- Tu1109 Evaluation of the Relationship Between Fecal Calprotectin Concentrations and Clinical and Endoscopic Outcome Measures in a Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis (2013) (7)
- 490 Postoperative Complications in a Population-Based Cohort of Crohn's Disease (2010) (6)
- Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. (2018) (6)
- OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis (2019) (6)
- Fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease (2003) (6)
- Comparable Pharmacokinetics (PK) of Two Delayed Release Formulations of Oral Mesalamine: 944 (2007) (6)
- Comparable pharmacokinetics of two delayed release formulations of oral mesalamine: P-043. (2008) (6)
- A randomized, double-blind, placebo-controlied trial of subcutaneous etanercept (p75 souble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohns' disease (2001) (6)
- Sa1209 Factors Affecting Adalimumab Pharmacokinetics in Adult Patients With Moderate to Severe CD (2013) (6)
- Medical therapy of Crohn disease (2004) (6)
- Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2: 984 (2007) (6)
- Sa1935 Population Pharmacokinetic Modeling Analysis of Golimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (2016) (6)
- 775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study (2021) (6)
- Efficacy and Safety of Ivarmacitinib in Patients with Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. (2022) (6)
- Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases (2022) (6)
- Inflammatory Bowel Disease: Therapy (2005) (6)
- ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. (2022) (6)
- P213 Influence of clinical history on scoring of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (6)
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues (2021) (6)
- Induction, Maintenance, and Sustainability of the Healing of Draining Fistulas in Patients with Crohnʼs Disease Treated with Adalimumab: Results of the CHARM Study (2006) (6)
- S1040 Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study) (2010) (6)
- Association between Week Eight Mayo Subscores and Hospitalization Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA 1 and ULTRA 2: 1683 (2013) (6)
- An Overview of Magnetic Resonance Enterography for Crohn’s Disease (2014) (6)
- Mid pouch strictureplasty for Crohn's disease after ileal–pouch anal anastomosis: an alternative to pouch excision (2005) (6)
- CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohnʼs Disease patients with open fistulas: O-0003. (2008) (6)
- Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. (2008) (6)
- 562 A Multi-Center National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy (2009) (6)
- DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis (2019) (6)
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (6)
- 865 Phase IIB, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Ulcerative Colitis (2014) (6)
- Dysregulation of the engulfment pathway in the gut fuels Inflammatory Bowel Disease (2018) (6)
- A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member) (2018) (6)
- P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (2013) (6)
- Biologic Therapy and Immunodulators are Associated with Decreased Risk of Cardiovascular Events in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis (2017) (6)
- 209 Prospective Therapeutic Drug Monitoring to Optimizing Infliximab (IFX) Maintenance Therapy in Patients With Inflammatory Bowel Disease (IBD) (2014) (6)
- Tu1119 Responsiveness of Central Endoscopic Assessment of Disease Activity Using the Modified Mayo Clinic Score in Ulcerative Colitis (2013) (6)
- Tracking Human Gut Microbiome Changes Resulting from a Colonoscopy (2017) (6)
- Mo1801 – Incorporating Fecal Calprotectin in Clinical Practice in Patients with Ulcerative Colitis: A Grade-Based Approach (2019) (5)
- Periperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease (2003) (5)
- Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis (2017) (5)
- 387 A Placebo-Controlled Trial of Visilizumab in Patients with Intravenous (IV) Steroid Refractory Ulcerative Colitis (UC) (2009) (5)
- 867 Anti-MAdCAM Monoclonal Antibody PF-00547659 Does Not Affect Immune Surveillance in the Central Nervous System of Crohn's Disease Patients Who Are Anti-TNF Inadequate Responders: Results From the Tosca Study (2014) (5)
- Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis (2005) (5)
- Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. (2011) (5)
- Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohnʼs Disease and in Those with Prior Infliximab Exposure: Results from an Open-Label Extension Study (2006) (5)
- Drug therapy of inflammatory bowel disease. (1995) (5)
- Evolving medical therapies for crohn’s disease (2001) (5)
- Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. (2018) (5)
- T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) (2008) (5)
- Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments: 607 (2017) (5)
- Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis (2021) (5)
- T1133 Efficacy and Tolerability of Certolizumab Pegol Are Sustained Over 18 Months: Data from PRECISE 2 and Its Extension Studies (PRECISE 3 and 4) (2008) (5)
- T1299 Emergency Room Visits and Hospitalizations for Crohn's Disease in a Population-Based Cohort (2010) (5)
- Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial: 1859 (2015) (5)
- The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews (2016) (5)
- Comment on ‘Anti-Adhesion Therapies and the Rule of 3 for Rare Events’ (2014) (5)
- Obesity is Associated with Inferior Response to Anti-TNF Therapy in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis (2017) (5)
- Adalimumab Induction Dose Reduces the Risk of Hospitalizations and Colectomies in Patients with Ulcerative Colitis During the First 8 Weeks of Therapy: 1601 (2012) (5)
- P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN’S DISEASE: RESULTS FROM FITZROY STUDY (2018) (5)
- Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Cimetidine in Seriously III Patients (1990) (5)
- Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis (2021) (5)
- 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis (2019) (5)
- P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease (2012) (5)
- Does the Surgical Failure Rate, Increased Incidence of Pouchitis, and Recent Findings of Dysplasia in Pouches Deter You from Recommending an Ileal Pouch‐Anal Anastomosis for Ulcerative Colitis? (1997) (5)
- P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (5)
- Sustainability of Adalimumab in Fistula Healing and Response: 2-Year Data from CHARM and 12-Month Open-Label Extension Follow-Up Study: 1034 (2007) (5)
- Therapeutic Approaches to the Treatment of Ulcerative Colitis (2010) (5)
- Chemical Impacts of the Microbiome Across Scales Reveal Novel Conjugated Bile Acids (2019) (5)
- Mo1794 Delayed Response to Golimumab Therapy: UC Patient Characteristics and Long-term Clinical Outcome: Post-Hoc Analyses from the PURSUIT Program (2016) (5)
- Risk Factors for Ulcerative Colitis (UC) Surgery in a Population-Based Cohort: 987 (2007) (5)
- Tu1849 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2020) (5)
- Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. (2014) (5)
- Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients: The ACT Trials (2005) (5)
- DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II (2019) (5)
- Transdermal Nicotine for Ulcerative Colitis: Reply (1997) (5)
- The safety profile of Azathioprine (AZA)/6-Mercaptopurine (6-MP) in the treatment of inflammatory bowel disease (IBD): a population-based study in Olmsted County, Minnesota (2003) (5)
- What you don't know might hurt you… (2002) (5)
- Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P-21 (2012) (5)
- Adalimumab Safety in Crohnʼs Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials: 1031 (2007) (5)
- 922 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease Through 2 Years (2008) (5)
- 847x Double Blind Placebo Controlled Phase IIB Trial of HMPL-004 (Andrographis Paniculata Extract) in Active Mild to Moderate Ulcerative Colitis (UC) (2010) (5)
- Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (2022) (5)
- Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies: 1716 (2013) (5)
- Sa1769 – Worldwide Incidence of Older-Onset Inflammatory Bowel Diseases in the 21ST Century: A Systematic Review of Population-Based Studies (2019) (5)
- Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (2013) (5)
- OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study (2021) (5)
- Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases (2021) (5)
- Treatment outcomes in lymphocytic collitis (2001) (5)
- Adalimumab therapy reduces hospitalization and Colectomy rates in patients with Ulcerative Colitis: Data from controlled trials: P-61. (2011) (5)
- Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years (2018) (5)
- Concurrent inflammatory bowel disease and the leukemias (1998) (5)
- Validation of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Its Correlation With Clinical Indices and Laboratory Measures of Disease Activity (2011) (5)
- The Long-Term, 30 Months, Efficacy and Tolerability of Certolizumab Pegol Therapy for Crohnʼs Disease: 1099 (2008) (5)
- P002 Adalimumab Maintains Long-Term Remission in Crohn's Disease through 2 Years (2008) (4)
- Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn's disease: Meta-analysis of Randomised controlled trials. (2021) (4)
- Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: 1524 (2012) (4)
- PILOT STUDY ON THE SAFETY AND EFFICACY OF GRANULOCYTE/MONOCYTE ADSORPTION APHERESIS WITH ADACOLUMN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 811 (2004) (4)
- Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients (2017) (4)
- A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY (2018) (4)
- Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years (2017) (4)
- Editorial: Use of Azathioprine and 6MP in Postoperative Crohn's: Changing Natural History or Just Along for the Ride? (2009) (4)
- T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial (2008) (4)
- Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases (2021) (4)
- Management of Crohn's disease (CD) of the ileoanal pouch with infixinab (2003) (4)
- National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. (2020) (4)
- Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease (2020) (4)
- S1096 Pre-Operative Infliximab Exposure and the Occurrence of Post-Operative Complications Following Proctocolectomy and Ileal Pouch-Anal Anastomosis (IPAA) for Ulcerative Colitis (UC) (2009) (4)
- Disease Activity Indices for Pouchitis: A Systematic Review. (2021) (4)
- Long-term remission with certolizumab pegol in Crohnʼs disease over 3.5 years: results from the PRECiSE 3 study: P-0027. (2009) (4)
- Sa1204 Deep Remission As a Predictor of Clinical Outcomes in Vedolizumab-Treated Patients With Ulcerative Colitis (2015) (4)
- T1130 Efficacy of Delayed-Release Oral Mesalamine in Patients Who Received Previous Ulcerative Colitis Treatment (2008) (4)
- Su1838 – Comparative Risk of Serious Infections with Biologic And/Or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis (2019) (4)
- Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease (2017) (4)
- S0703 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials (2020) (4)
- Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. (2020) (4)
- Adalimumab induction therapy improves health-related quality of life in patients with moderately to severely active ulcerative colitis. (2011) (4)
- Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. (1990) (4)
- Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis (2020) (4)
- Sa1203 Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies (2013) (4)
- Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study (2022) (4)
- P021 SUBCUTANEOUS CERTOLIZUMAB PEGOL IS WELL TOLERATED BY PATIENTS WITH ACTIVE CROHN'S DISEASE: RESULTS FROM TWO PHASE III STUDIES (PRECISE 1 AND 2) (2007) (4)
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for thiopurine methyltransferase (TPMT) genotype and thiopurine dosing (2011) (4)
- The Effectiveness of Continuing the Induction Dose of Asacol into the Maintenance Phase: Results from the Community Setting (2005) (4)
- 800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study (2019) (4)
- OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM (2018) (4)
- OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study (2021) (4)
- DOP023 Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials (2018) (4)
- Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy: 570 (2016) (4)
- Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebo-controlled trial (2016) (4)
- 9 Assessment of Certolizumab Pegol in the Treatment of Crohn's Disease in Patients for Whom Infliximab Treatment was not Successful: Open-Label Induction Preliminary Results from the Welcome Study (2008) (4)
- S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies (2021) (4)
- Mo1222 Effects of Continued Vedolizumab Therapy for Ulcerative Colitis in Week 6 Induction Therapy Nonresponders (2014) (4)
- Skipping of Distal Terminal Ileum in Crohn's Disease (2011) (4)
- Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti‐TNF Antagonist Failure: A Randomized, Placebo‐controlled, Double‐blind, Multicenter Trial: P‐26 (2012) (4)
- Effect of adalimumab induction therapy on clinical laboratory parameters suggesting improved nutrition and inflammation status in patients with moderately to severely active ulcerative colitis. (2011) (4)
- Early infection with measles virus is associated with an increased risk of ulcerative colitis (1998) (4)
- Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. (2022) (4)
- MMX™ mesalamine Therapy for the Induction of Remission Beyond 8 Weeks: How Long Before Symptom Resolution? (2008) (4)
- Why innovation in inflammatory bowel disease drug development will impact your practice. (2011) (4)
- 962 Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Levels in Patients with Inflammatory Bowel Disease (2009) (4)
- P067 Natalizumab Induces Sustained Response and Remission in Crohn's Patients With Previous Infliximab Failure: Results From The Encore Trial (2007) (4)
- CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. (2022) (4)
- 90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial (2013) (4)
- S777 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials (2021) (4)
- Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension: 571 (2016) (4)
- 1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2009) (4)
- P-101 Incidence of Anti-drug Antibodies in Crohn's Disease Patients During 5 Years of Certolizumab Pegol Therapy (2016) (4)
- Association of Steroid-Free Clinical Remission and Complete Mucosal Healing at 6 Months With Clinical Outcome at 1 Year: A Post-Hoc Analysis of SONIC trial Data (2011) (4)
- Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? (1998) (4)
- The relationship between endoscopic and clinical recurrence in postoperative Crohn's disease: a systematic review and meta-analysis. (2021) (4)
- Obesity is Associated with Worse Disease Activity in Patients with Inflammatory Bowel Diseases: An Internet Based Cohort Study (2017) (4)
- 537 ENDOSCOPY AND SYSTEMATIC BIOPSY OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS LEADS TO HIGH DISCOVERY RATE OF PATIENTS WHO MEET HISTOLOGIC CRITERIA FOR EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS (2021) (4)
- PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (4)
- Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials. (2022) (4)
- Corticosteroid Dose Reduction With Vedolizumab Treatment of Crohnʼs Disease During the GEMINI 2 Trial: 1857 (2015) (4)
- 904 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 4.4 Years of Safety Data from Global Clinical Trials (2019) (4)
- The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. (2021) (4)
- Mo1217 Effects of Continued Vedolizumab Therapy for Crohn's Disease in Week 6 Induction Therapy Nonresponders (2014) (4)
- P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1 (2019) (4)
- Efficacy of Ustekinumab for Induction and Maintenance of Histological Healing in patient's with Crohn’s Disease (2017) (4)
- Reply to Lama (2004) (4)
- A double-blind, 377-subject randomized study identifies Ruminococcus, Coprococcus, Christensenella, and Collinsella as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides (2021) (4)
- The Value of a Central Image Management System (CIMS) in the Conduct of Randomized Controlled Trials of Therapy for Ulcerative Colitis (UC): 1454 (2012) (4)
- Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? (2002) (4)
- Effect of disease duration on 'deep remission': Results from the EXTEND trial (2010) (4)
- P284 Agreement of central readers in the evaluation of histopathological disease activity in ulcerative colitis (2014) (4)
- Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. (2015) (4)
- 637 Clinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease (2019) (4)
- Microsimulation Model to Determine the Cost Effectiveness of Treat to Target Strategies for Ulcerative Colitis. (2020) (4)
- P395 Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS). (2017) (3)
- O-002 Evaluation of the Operating Properties of Candidate Patient Reported Outcomes for Use in Randomized Controlled Trials in Crohn’s Disease (2013) (3)
- Sa1196 Responsiveness of Endoscopic Indices in the Evaluation of Ulcerative Colitis (2014) (3)
- P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II) (2019) (3)
- P006 Adalimumab Maintains Long-Term Remission in Crohn's Disease after Infliximab Failure: 1-Year Follow-up of Gain Trial (2008) (3)
- Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies: P‐30 (2012) (3)
- Time-In-Remission Analysis of Adalimumab vs. Placebo for the Treatment of Ulcerative Colitis: 1590 (2012) (3)
- S1058 Certolizumab Pegol Improves Health-Related Quality of Life in Crohn's Disease Patients for Whom Infliximab Treatment Was Not Successful: Results from the WELCOME Study (2009) (3)
- Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. (2020) (3)
- The future of inflammatory bowel disease care. (2009) (3)
- S0705 Evaluation of Symptom Improvement During Induction in Patients With Crohn's Disease Treated With Mirikizumab (2020) (3)
- A population-based estimate of corticosteroid dependence and resistance in ulcerative colitis (2001) (3)
- New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? (2015) (3)
- 44 Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study) (2010) (3)
- Su2087 Effect of Long-Term Budesonide MMx 6 mg use on Bone Mineral Density in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study (2012) (3)
- Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study (2021) (3)
- DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study (2020) (3)
- Treatment guidelines and clinical practice: Optimizing foundational therapies for ulcerative colitis (2008) (3)
- P386 Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease (2014) (3)
- P-057 Reliability of Central Readers in the Evaluation of Endoscopic Disease Activity in Crohn’s Disease (2013) (3)
- P128 The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC) (2013) (3)
- Is there a role for infliximab in the treatment of severe ulcerative colitis?: The American experience (2008) (3)
- P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial (2019) (3)
- Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study: 1709 (2014) (3)
- Sa1249 Infliximab and Antibody to Infliximab Concentrations in 7,613 Patients Shows Indication for Testing, Association With Loss of Response and Provides New Insights Into Binding Characteristics of Anti-Drug Antibodies (2014) (3)
- S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study (2020) (3)
- DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis. (2017) (3)
- Effect of Adalimumab Induction Therapy on Clinical Laboratory Parameters Suggesting Improved Nutrition and Inflammation Status in Patients with Moderately to Severely Active Ulcerative Colitis: 1177 (2010) (3)
- Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. (2012) (3)
- P-103 Refinement of Population Pharmacokinetic Model of Certolizumab Pegol in Crohn's Disease Patients to Account for Time Varying Nature of Covariates (2016) (3)
- Disability in Inflammatory Bowel Disease (IBD): Developing Icf Core Sets for Patients With IBD Based on the WHO International Classification of Functioning, Disability and Health (2011) (3)
- Sa1220 Budesonide MMx® 9 mg Induces Remission in Mild-to-Moderately Active UC Patients Regardless of Prior History of 5-ASA Therapy (2013) (3)
- Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients (2020) (3)
- Retrospective review of the role of intravenous iron replacement therapy in treatment of anemia in patients with inflammatory bowel disease (2003) (3)
- Intravenous azathioprine in severe ulcerative colitis: a pilot study (2000) (3)
- DOP074 Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients. (2017) (3)
- Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives (2016) (3)
- Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY (2021) (3)
- S1064 Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME Study (2009) (3)
- 460 RAPID INDUCTION EFFECTS OF OZANIMOD ON CLINICAL SYMPTOMS AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PHASE OF TRUE NORTH (2021) (3)
- Maintenance therapy with natalizumab improves quality of life in patients with Crohn's disease (2005) (3)
- Sustained Clinical Remission of Ulcerative Colitis is Associated with Greater Improvements in Quality of Life, Work Productivity and Activity: 1210 (2011) (3)
- Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis Among Initial Responders: 1592 (2012) (3)
- T1129 Predictors of Response in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Multiple Regression Analysis of PRECISE 2 Data (2008) (3)
- P552 Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2 (2014) (3)
- Su1289 Development of Red Flags for Early Referral of Adults With Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative (2014) (3)
- 857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis (2016) (3)
- Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: O‐1a (2012) (3)
- Evaluation of CT Enterography (CTE), Biomarkers, and Clinical Symptoms for the Non-Invasive Prediction of Active Inflammation in Patients with Crohnʼs Disease: 1118 (2008) (3)
- Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. (2021) (3)
- Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease: 1025 (2007) (3)
- Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial (2022) (3)
- Time to Initial Symptom Resolution with MMX™ Mesalamine Therapy for Active, Mild-to-Moderate Ulcerative Colitis: 938 (2007) (3)
- Mucosal Healing in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P‐20 (2012) (3)
- Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. (2021) (3)
- Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. (2023) (3)
- Regain of Response and Remission by Dose Adjustment in Patients with Crohnʼs Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study: 1214 (2009) (3)
- Targeted delivery of azathioprine (AZA) to the ileum and colon for the treatment of Crohn's disease (CD): Scintigraphic and pharmacokinetic (PK) evaluation of a novel azathioprine delayed-release (AZA-DR) formulation (2001) (3)
- DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. (2017) (3)
- Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. (2021) (3)
- P-149 Efficacy and Safety of Budesonide Foam for Inducing Remission in Mildly to Moderately Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis (2013) (3)
- Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (3)
- T1142 Infliximab Treatment for Ulcerative Colitis: Clinical Response, Clinical Remission, & Mucosal Healing in Patients with Moderate or Severe Disease in the Active Ulcerative Colitis Trials (ACT1 & ACT2) (2008) (3)
- P568 Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2 (2013) (3)
- Antibodies Against Certolizumab Pegol (CZP), Plasma Concentrations of CZP and Efficacy in Patients with Crohnʼs Disease Receiving Continuous CZP Therapy with or without Concomitant Immunosuppressants: 1172 (2011) (3)
- Identification of Subgroups of Adalimumab-Treated Patients With Crohn's Disease Who Experience High Rates of Deep Remission (2011) (3)
- COLLAGENOUS COLITIS, BUT NOT LYMPHOCYTIC COLITIS, IS ASSOCIATED WITH CIGARETTE SMOKING: 359 (2004) (3)
- DOP073 Efficacy of induction treatment with vedolizumab for patients with Crohn's disease who have experienced tumour necrosis factor antagonist failure or are tumour necrosis factor antagonist naive (2014) (3)
- Non-cirrhotic Portal Hypertension Due to 6-Mercaptopurine Use for Crohn’s Disease (2014) (3)
- Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. (2022) (3)
- Achievement of Early Deep Remission Is Associated with Lower Rates of Weekly Dosing for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND: 1208 (2010) (3)
- Rapid onset of adalimumab and long-term efficacy among week-8 responders in adults with moderate to severe active Ulcerative Colitis: O-7. (2011) (3)
- 389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis (2009) (3)
- Randomized, Double-blind, Placebo-Controlled Trial of Andrographis Paniculata Extract (HMPL-004) in Patients with Moderately Active Crohnʼs Disease: 1180 (2010) (3)
- Sa1219 Efficacy of Budesonide MMx® in Reduction of Symptoms in Patients With Mild-to-Moderately Active Ulcerative Colitis: A Pooled Analysis of the CORE I and CORE II Studies (2013) (3)
- Induction of Clinical and Endoscopic Remission of Mild to Moderately Active Ulcerative Colitis With Budesonide MMX (R) 9 mg: Analysis of Pooled Data from Two Phase 3 Studies (2011) (3)
- W1092 Maintenance of Long-Term Remission in Patients with Moderately to Severely Active Crohn's Disease Treated for 3 Years with Adalimumab: Results from the Open-Label ADHERE Study (2009) (3)
- Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis (2013) (3)
- Natalizumab reduces the rate of hospitalization in moderate to severe Crohnʼs Patients: Evidence from the Clinical Trial Program: P-0068. (2009) (3)
- Early remission status predicts long-term outcomes in patients with Crohn’s disease treated with certolizumab pegol (2016) (3)
- Adalimumab Induction Therapy Improves Health-Related Quality of Life in Patients with Moderately to Severely Active Ulcerative Colitis: 1207 (2010) (3)
- Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately‐to‐Severely Active Ulcerative Colitis: ULTRA 2 Subanalysis: P‐22 (2012) (3)
- Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up: 595 (2017) (3)
- Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease (2017) (3)
- Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease (2016) (3)
- Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium: 1904 (2015) (3)
- Limited Clinical Utility of a Self-Administered Tool for Predicting Medication Adherence Behavior in IBD (2011) (3)
- Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study (2022) (3)
- P493 Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD (2013) (2)
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (2023) (2)
- M1235 Different Simple Clinical Colitis Activity Index (SCCAI) Cut-off Points Used to Define Remission of Ulcerative Colitis (UC) in Large Mesalamine Study (2010) (2)
- 832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies (2019) (2)
- Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments: 709 (2016) (2)
- Open maintenance treatment with transdermal nicotine: Long-term results after a randomized, double-blind, placebo-controlled trial for active ulcerative colitis* (1998) (2)
- P057 MMX Mesalazine is an Effective Treatment for Men And Women With Mild-To-Moderate, Active Ulcerative Colitis (2007) (2)
- Rapid Improvement of Patient-reported CDAI Diary Components by Day 8 in Active Crohnʼs Disease Patients Treated with Certolizumab Pegol: 1194 (2009) (2)
- Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohn's Disease: Subanalysis of CHARM: 922 (2007) (2)
- Oral nicotine in the treatment of primary sclerosing cholangitis: A pilot study (1998) (2)
- S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study (2020) (2)
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023) (2)
- 634 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program (2019) (2)
- No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy (2021) (2)
- OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension. (2017) (2)
- S1035 Certolizumab Pegol is Effective at Maintaining Response and Remission in Patients With Fistulising Crohn's Disease: 3-Year Results From the PRECiSE 3 Study (2010) (2)
- Tu1934 Assessment of Serum C-Reactive Protein, Fecal Lactoferrin, and Fecal Calprotectin in Patients With Moderate-Severely Active Crohns Disease: Results From the IM UNITI Maintenance Study (2016) (2)
- P162 Induction of clinical and endoscopic remission with budesonide MMX in mild to moderately active ulcerative colitis: Pooled data from two phase 3 studies (2012) (2)
- P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data (2020) (2)
- The Evolution of Crohnʼs Disease (CD) Behavior in a Population-Based Cohort: 1135 (2008) (2)
- 764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study (2019) (2)
- A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease (2021) (2)
- A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohnʼs Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598 (2017) (2)
- Long-term remission with certolizumab pegol in Crohn's disease (2011) (2)
- Su2084 Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction (2012) (2)
- Studies in human intestinal tissues: is it time to reemphasize research in human immunology? (2014) (2)
- P083 - Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM (2009) (2)
- Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials: 1721 (2013) (2)
- Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials: 569 (2016) (2)
- Baseline Corticosteroid Use and Corticosteroid‐Free Clinical Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial: P‐25 (2012) (2)
- S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE (2020) (2)
- P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SC (2013) (2)
- Best of DDW 2007: Highlights from the 2007 digestive disease week May 19-24, 2007, Washington, DC (2007) (2)
- Sa1759 - Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data Adjusting for Both Induction and Remission Phases and Prior Exposure to TNF Antagonists (2018) (2)
- DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis (2018) (2)
- P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study (2018) (2)
- 110 Stool DNA Methylation Markers for the Detection of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease (2012) (2)
- DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension (2020) (2)
- S1037 Certolizumab Pegol Demonstrates Efficacy in Maintaining Response and Remission in Patients With Active Crohn's Disease Regardless of Their Immunosuppressant Treatment Status at Entry to the PRECiSE 2 Study (2010) (2)
- P120 Prevalence of endoscopic improvement and endoscopic remission according to patient reported outcomes in ulcerative colitis (2020) (2)
- 1000 Agreement Among Central Readers in the Evaluation of Endoscopic Disease Activity in Crohn's Disease (2014) (2)
- Su1910 EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS TREATED-TO-TARGET: COMPARISON OF CLINICAL VS ENDOSCOPIC VS HISTOLOGIC REMISSION (2020) (2)
- 132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE (2021) (2)
- P113 Short-Term Adalimumab Therapy Improves Quality of Life in Patients Who had Failed Infliximab Therapy: Results From the Gain Trial (2007) (2)
- A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS (2018) (2)
- Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. (2014) (2)
- Long-term Remission with Certolizumab Pegol in Crohnʼs Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study): 1152 (2010) (2)
- Early Symptomatic Response and Mucosal Healing With Mesalamine Rectal Suspension Therapy in the Treatment of Active Distal Ulcerative Colitis (UC): Additional Results From Two Controlled, Randomized Trials (2011) (2)
- Mo1867 - Shorter Disease Duration is Associated with Higher Response Rates to Vedolizumab in Crohn's Disease but not Ulcerative Colitis: A Multi-Center Consortium Analysis (2018) (2)
- Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases (2021) (2)
- 16 Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial (2013) (2)
- Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. (2021) (2)
- 864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive (2014) (2)
- Su1921 Frequency and Yield of Computed Tomography (CT) Scan Imaging in the Emergency Department in Patients With Inflammatory Bowel Disease (IBD) (2012) (2)
- Once Daily Dosing of Delayed-Release Oral Mesalamine (400 mg Tablet) is as Effective as Twice Daily Dosing for Maintenance of Remission of Ulcerative Colitis: Results of the QDIEM Study: 1185 (2009) (2)
- Long‐Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: P‐19 (2012) (2)
- 835 – Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results from the Gemini Lts Study (2019) (2)
- MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis: P-0049. (2007) (2)
- Investigation of a potential drug interaction between azathioprine (AZA)/6-mercaptopurine (6MP) and sulfasalazine (SAS), mesalamine (Pentasa) or balsalazide among patients with Crohn's disease (CD) (2000) (2)
- Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort. (2020) (2)
- Sa1258 Comparison of Real-World Outcomes of Adalimumab (ADA) and Infliximab (IFX) for Patients With Ulcerative Colitis (UC) in the United States (2015) (2)
- T1126 Response and Remission At 18 Months of Certolizumab Pegol in Patients with Active Crohn's Disease Is Not Influenced By Rapidity and Magnitude of Induction: An Analysis of PRECISE 2 and 3 (2008) (2)
- CHAPTER 40 – POUCHITIS AND FUNCTIONAL COMPLICATIONS OF THE PELVIC POUCH (2005) (2)
- OP31 Meta–omics reveals microbiome-driven proteolysis as a contributing factor to the severity of ulcerative colitis disease activity (2020) (2)
- 535 Soluble MAdCAM-1: A Potential Biomarker for Response to Vedolizumab (2015) (2)
- P394 Rate of and response to dose escalation in patients treated with adalimumab for moderately to severely active ulcerative colitis: subanalysis of ULTRA 2 (2013) (2)
- A new treatment option for ulcerative colitis. (2007) (2)
- Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis (2015) (2)
- Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2 (2013) (2)
- Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice (2016) (2)
- P019 Subcutaneous Certolizumab Pegol is Effective in Patients With Prior Infliximab Exposure, or Concomitant Immunosuppressant or Glucocorticoid Treatment: Data From Precise 2 (2007) (2)
- Su1276 αE Integrin Expression As a Predictive Biomarker for Induction of Clinical Remission by Etrolizumab: Analysis of a Phase II Trial in Moderate-to-Severely Active Ulcerative Colitis (2014) (2)
- Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION (2020) (2)
- Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
- A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance: 1665 (2012) (2)
- Tu2056 Safety and Efficacy of GS-5745 an Anti-Matrix Metalloproteinase 9 (MMP) Monoclonal Antibody in Patients With Moderately to Severely Active Ulcerative Colitis (2015) (2)
- MMX Mesalamine, a Novel Formulation of 5-ASA, Effectively Induces the Remission of Active Mild-to-Moderate Ulcerative Colitis in Men and Women: 1103 (2006) (2)
- OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension (2014) (2)
- SAFETY OF CELECOXIB IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION: 794 (2004) (2)
- Su1745 Characterization of Molecular Response to Golimumab in Ulcerative Colitis by mRNA Expression Profiling: Results From Pursuit-SC Induction Study (2013) (2)
- P391 Rates of “patient-defined” remission with adalimumab in patients with ulcerative colitis: subanalysis of ULTRA 1 and ULTRA 2 (2013) (2)
- Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium (2016) (2)
- P005 Analysis of Predictors of Response Maintenance to Certolizumab Pegol in Patients with Active Crohn's Disease: Data from Precise 2 (2008) (2)
- S0652 Real World Exposure-Response Relationship of Vedolizumab in Inflammatory Bowel Disease: A Pooled Multicenter Observational Cohort Analysis of Clinical and Modeled Pharmacological Data (2020) (2)
- Sa1878 – Effects of Subcutaneous Vedolizumab on Health-Related Quality of Life and Work Productivity in Patients with Ulcerative Colitis: Results from the Phase 3 Visible 1 Trial (2019) (2)
- PTU-108 Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I (2012) (2)
- P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial (2018) (2)
- Covariates Influencing the Exposure-Response Relationship for Certolizumab Pegol During the Induction and Maintenances Phases in Patients with Crohnʼs Disease: 572 (2016) (2)
- Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads (2019) (2)
- Clinical Utility of Next Generation Infliximab and Antibodies to Infliximab Assay: 1745 (2013) (2)
- MMX™ Mesalamine Is Effective for the Maintenance of Remission of Mild-to-Moderate Ulcerative Colitis Irrespective of Patients’ Previous Relapse History: 935 (2007) (2)
- 328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (2)
- OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis (2014) (2)
- Drug development for ulcerative proctitis: current concepts (2021) (2)
- Rapid Symptom Resolution with Delayed-Release Mesalamine 4.8g/d Compared to 2.4g/d in Moderately Active Ulcerative Colitis Patients with a History of More Difficult to Treat Disease: 1209 (2009) (2)
- Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial (2019) (2)
- A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy (2023) (2)
- Tu1213 Reproducibility of Magnetic Resonance Enterography Assessment of Disease Activity in Crohn's Disease Using Central Readers (2015) (2)
- Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod (2019) (2)
- The start of a new journal (2003) (2)
- T1245 Efficacy of Biologics in Crohn's Disease (CD): A Meta-Analysis of Randomized Controlled Trials Looking at Inducing Remission in Active Disease and Preventing Relapse Rates in Quiescent Disease (2010) (2)
- Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium (2017) (2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster: 1227 (2011) (2)
- Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies (2022) (2)
- Azathioprine-induced neuro-psychiatric disorders. (2014) (2)
- Certolizumab Pegol Is Efficacious in Crohnʼs Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure: 1103 (2008) (2)
- ADALIMUMAB, A HUMAN ANTI-TNF-α MONOCLONAL ANTIBODY, INDUCES CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHNʼS DISEASE IRRESPECTIVE OF SMOKING STATUS: 800 (2004) (2)
- A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis: ACT I Trial Results through Week 54 (2005) (2)
- Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately to Severely Active Ulcerative Colitis: Subanalysis of ULTRA 2: 1541 (2012) (2)
- Variation in Severity Assessment and Initial Mesalamine Dose Selection for Ulcerative Colitis in Community Practice (2006) (2)
- 91 Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Crohn's Disease in Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study (2013) (2)
- OP05 Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease (2012) (2)
- Charging ahead in IBD: Challenging issues and recent breakthroughs - A report of a symposium presented on May 19, 2008 San Diego, California (2008) (2)
- Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT‐SC Induction: P‐69 (2012) (2)
- A six-month open label assessment of steroid sparing properties of CDP571, a humanized antibody to TNFA in steroid dependent patients with Crohn's disease (2000) (2)
- 481 Noninvasive Detection of Colorectal Neoplasia (CRN) in Inflammatory Bowel Disease (IBD) by Stool DNA Testing: A Pilot Study (2010) (2)
- Budesonide capsules prolong time to relapse in Crohn's disease patients with medically induced remission (2003) (2)
- P-148 Budesonide MMX Versus Placebo in Patients with Active, Mild-to-Moderate Ulcerative Colitis who Were 5-ASA Naïve or Previously Treated with 5-ASA (2013) (2)
- Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. (2021) (2)
- DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity (2020) (2)
- DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis (2019) (2)
- 775c A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients. (2021) (2)
- P225 Impact of subcutaneously administered golimumab on disease specific and generic health-related quality of life in patients with moderately to severely active ulcerative colitis: Results from PURSUIT-SC induction (2013) (2)
- P019 LONG-TERM FISTULA HEALING AND RESPONSE WITH ADALIMUMAB TREATMENT: 2-YEAR DATA FROM CHARM INCLUDING 1-YEAR OPEN-LABEL EXTENSION (2008) (2)
- P018 Certolizumab Pegol is Effective in Patients Regardless of CRP Level And Disease Duration: Data From Precise 2 (2007) (2)
- P043 Long-Term Steroid-Free Remission in Crohn's Patients Receiving Adalimumab: The Charm Trial (2008) (2)
- The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. (2016) (2)
- 995 Feasibility, Precision and Reproducibility of MR Enterography for Detection of Inflammation in Crohn's Disease in a Multicenter Clinical Trial (2014) (2)
- Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. (2022) (2)
- Inflammatory bowel disease: a new combination therapy for pouchitis. (2005) (2)
- PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis (2012) (2)
- MMX Mesalamine Is Well Tolerated in Patients with Active Mild-to-Moderate Ulcerative Colitis: Pooled Analysis of Adverse Events from Three Randomized Studies (2006) (2)
- Corticosteroid dependent and resistant Crohns disease (2000) (2)
- Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials (2021) (2)
- P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019 (2020) (2)
- Determination of the minimally important difference in WPAI: CD score that indicates a relevant impact on work productivity: P-046. (2008) (2)
- DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis (2018) (2)
- Long-term Remission with Certolizumab Pegol in Crohnʼs Disease over 3.5 Years: Results from the PRECiSE 3 Study: 1213 (2009) (2)
- Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study Data (2014) (2)
- Tu1717 – Tofacitinib for the Treatment of Ulcerative Colitis: Up to 5.4 Years of Safety Data from Global Clinical Trials (2019) (2)
- Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm (2018) (2)
- P257 Importance of deep remission compared with mucosal healing only: Results from EXTEND (2012) (2)
- MMX Mesalamine for the Treatment of Active Mild-to-Moderate Ulcerative Colitis: An Evidence-Based Medicine Analysis (2006) (2)
- Positioning Biologics and Small Molecules in the Management of Moderate to Severe IBD. (2021) (2)
- The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium (2022) (2)
- 325 - Factors Driving Treatment Escalation in Crohn's Disease in the Calm Trial (2018) (2)
- S0779 Effect of Ustekinumab Maintenance Therapy on Stool Frequency and Rectal Bleeding Through 2 Years in the UNIFI Phase 3 Study in Ulcerative Colitis (2020) (1)
- Su1191 Clinical Features and Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids (2012) (1)
- W1195 Safety of Thiopurines in a Population-Based Cohort of Inflammatory Bowel Disease (2010) (1)
- Rapid Symptom Resolution with Delayed Release Mesalamine in Mildly and Moderately Active UC: 943 (2007) (1)
- Infliximab Reduces UC-Related Hospitalizations Requiring High-Dose Corticosteroids: 1052 (2006) (1)
- T1135 Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo-Controlled Trials (2008) (1)
- Sa1135 Serious Infectious Complications in Patients Treated With Certolizumab Pegol: A Pooled Analysis of 15 Crohn's Disease Global Clinical Trials (2015) (1)
- Su1062 Placebo Response and Remission Rates in Ulcerative Colitis Clinical Trials: Systematic Review and Meta-Analysis (2015) (1)
- P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis (2020) (1)
- Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohnʼs Disease Patients: 842 (2005) (1)
- EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY: 831 (2004) (1)
- 772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II (2019) (1)
- Safety of Adalimumab in Global Clinical Trials of Patients with Crohnʼs Disease: 1142 (2010) (1)
- Budesonide Foam for Inducing Remission in Active Mild-to-moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Results of Two Randomized, Placebo-controlled Trials: 1799 (2013) (1)
- P373 Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results (2019) (1)
- Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohnʼs Disease with Secondary Infliximab Failure: 1217 (2009) (1)
- Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohnʼs disease: P-069. (2008) (1)
- T1244 Efficacy of Anti-TNF α Therapy in Ulcerative Colitis (UC): A Meta-Analysis of Randomized Controlled Trials Looking at Inducing Remission in Active Disease and Preventing Relapse Rates in Quiescent Disease (2010) (1)
- Su1959 NATURAL HISTORY OF ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF POPULATION-BASED COHORT STUDIES (2020) (1)
- Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply (2020) (1)
- Mo1916 – Effectiveness and Safety of Ustekinumab for Crohn’s Disease in Routine Clinical Practice (2019) (1)
- Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis. (2020) (1)
- Interpretation of Anti-TNF Drug Concentration and Antibody Levels in IBD: A Mobile App to Guide Management Based on Results From a RAND Appropriateness Panel: 1726 (2014) (1)
- Efficacy of Certolizumab Pegol in Crohnʼs Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications: 1216 (2009) (1)
- Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn’s Disease: An Analysis of the PRECiSE 3 Study: 1722 (2014) (1)
- Rapid symptom resolution with delayed release mesalamine in mildly and moderately active ulcerative colitis: P-042. (2008) (1)
- 558 Influence of Symptom Knowledge and History on Disease Scoring With the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (1)
- Positive outcomes for etrasimod in UC (2022) (1)
- Vedolizumab does not Increase the Risk of Enteric Infections as Compared to Infliximab: A Retrospective Cohort Study (2017) (1)
- Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS. (2020) (1)
- Risk of fracture in Crohn's disease: A population-based study (2001) (1)
- Tu1884 - Improvement of Clinical Symptoms of Lactose Intolerance with a Novel Prebiotic Galacto-Oligosaccharide, RP-G28 (2018) (1)
- Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. (2022) (1)
- Sa1190 Early Remission Status As a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis From the PRECiSE 3 Study (2015) (1)
- 884a: THE IDEAL STUDY: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL α4β7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (2022) (1)
- Fecal lactoferrin is a sensitive and specific marker for chronic inflammatory bowel diseases (2001) (1)
- Induction of Remission with Adalimumab in Patients with Moderate Crohnʼs Disease: Subanalysis of CLASSIC I: 1166 (2011) (1)
- Improvement in health related quality of life in infliximab-treated moderate-tosevere active ulcerative colitis patients: Improvement overall and by baseline disease activity: O-0019. (2007) (1)
- Su1084 Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease (2014) (1)
- Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy (2003) (1)
- Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab: 858 (2005) (1)
- N-acetyltransferase (NAT) 1 and 2 genotypes do not predict response or toxicity to treatment with 5-ASA and sulfasalazine in a population-based cohort of patients with ulcerative colitis (UC) (2001) (1)
- Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease (2019) (1)
- Incidence of Post-Surgical Complications among Ulcerative Colitis (UC) Patients (Pts): A Population-Based Study: 986 (2007) (1)
- T1012 Long-Term Maintenance of Clinical Remission With Reduced Dosing Frequency of Adalimumab in Patients With Moderate to Severe Crohn's Disease (2010) (1)
- P-0061: The long-term, 30-month, efficacy and tolerability of Certolizumab Pegol Therapy for Crohn's Disease (2008) (1)
- Best of DDW 2006. (2006) (1)
- Poster PresentationsP011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS (2008) (1)
- 412 CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH (2021) (1)
- P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2 (2013) (1)
- Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis (2015) (1)
- Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy: P‐61 (2012) (1)
- Baseline C-reactive protein is associated with disease progression in patients with Crohnʼs disease: P-34. (2011) (1)
- Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS (2020) (1)
- P281 A serum biomarker panel can accurately identify the presence of mucosal ulcers in patients with Crohn’s disease (2020) (1)
- P213 Benefit risk assessment of adalimumab as maintenance treatment for ulcerative colitis: Near analysis of week 8 responders in ULTRA 2 (2012) (1)
- Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. (2021) (1)
- Comment to Letter to the Editor (2000) (1)
- W1095 Natalizumab Use in Clinical Practice in Patients with Moderate to Severe Crohn's Disease (2009) (1)
- Sustained Mucosal Healing in Adalimumab-Treated patients with moderate to severe Ileocolonic Crohnʼs Disease: Results of the EXTEND Trial: P-0028. (2009) (1)
- P114 Adalimumab Safety in Crohn's Disease: A Sub-Analysis of Immunosuppressant and Steroid Use in the Charm Trial (2007) (1)
- Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Crohnʼs Disease: 1684 (2013) (1)
- Association of Vedolizumab Concentrations Using Anser: Mobility Shift Assay and Clinical Response in IBD Patients in Clinical Practice: 599 (2016) (1)
- P448 Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. (2017) (1)
- Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohnʼs Disease: Results from PRECiSE 2: 1204 (2011) (1)
- Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice (2016) (1)
- P403 Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE (2012) (1)
- Highlights in Anti – Tumor Necrosis Factor Monitoring Digestive Disease Week 2012 May 19 – 22 (2012) (1)
- Induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis in patients treated with MMX® mesalamine: established versus newly diagnosed disease: P-0092. (2009) (1)
- Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. (2018) (1)
- Inflammatory Biomarkers and Clinical Remission in Patients with Active Crohnʼs Disease: Results from PRECiSE 2: 1176 (2011) (1)
- Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. (2022) (1)
- Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment: O-033. (2008) (1)
- Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis (2014) (1)
- S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension (2020) (1)
- A tissue atlas of ulcerative colitis to guide TNF inhibitor therapy (2021) (1)
- 945 HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY (2020) (1)
- Tu1835 – Association Between Vedolizumab Trough Concentration and Clinical Outcomes in Patients with Inflammatory Bowel Diseases: Implications for Clinical Practice (2019) (1)
- Is the anti-inflammatory action of methotrexate mediated by adenosine? (1998) (1)
- P-026 Effect of Standardized Scoring Conventions on Inter-Rater Reliability in the Endoscopic Evaluation of Crohn's Disease (2016) (1)
- Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award: 605 (2016) (1)
- Baseline C-reactive protein (CRP) and plasma anti-TNF concentration in patients with active Crohnʼs disease treated with certolizumab pegol: P-30. (2011) (1)
- Extraintestinal Manifestations of Inflamamtory Bowel Disease (2003) (1)
- Effect of disease duration on ‘deep remission’ (2011) (1)
- MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis (2007) (1)
- Early Responses in Patient-reported Outcomes Are Predictors for Mucosal Healing in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Golimumab: Results from PURSUIT SC Induction: 1723 (2013) (1)
- A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohnʼs Disease: 727 (2017) (1)
- Development of a simplified, patient-based Crohn's disease activity index (2001) (1)
- Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy: 1022 (2007) (1)
- OP033 Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor. (2017) (1)
- P033 EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY (2019) (1)
- Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P‐21 (2012) (1)
- Adalimumab Therapy Reduces Hospitalization Rates in Patients With Ulcerative Colitis Among Initial Responders: P‐60 (2012) (1)
- 543 Intestinal Wall Remodeling Measured With Serial CT Enterography in Patients With Crohn's Disease Treated With Infliximab (2010) (1)
- A moveable feast. (2018) (1)
- Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: established versus newly diagnosed disease: P-0096. (2009) (1)
- S1183 Postoperative Recurrence of Crohn's Disease in a Population-Based Cohort (2010) (1)
- 950 THE VISIBLE 2 PHASE 3 STUDY OF EFFICACY AND SAFETY OF VEDOLIZUMAB SC FOR MODERATE-TO-SEVERE CROHN'S DISEASE (2020) (1)
- S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study (2021) (1)
- Su1786 – Reduction in Costs of Care in Patients with Crohn’s Disease in a Community Practice-Based Medical Home Over Two Years: A Propensity Score Matched Cohort Analysis (2019) (1)
- Adalimumab Maintenance Therapy Is Associated with a Reduced Risk of Major Surgery: 965 (2008) (1)
- Updates from the front lines of Crohn's disease: Achieving a balance between safety and efficacy (2008) (1)
- Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND (2014) (1)
- S0783 Markedly Elevated 7-α-hydroxy-4-cholesten-3-one (C4) Is Associated With Fat Malabsorption in the Setting of Short Bowel Syndrome (2020) (1)
- P171 A multi-marker serum test predicts mucosal healing status in Crohn’s disease regardless of disease location (2018) (1)
- Objectifying the Crohnʼs Disease Activity Index (CDAI): Can We Teach an Old Score New Tricks?: Presidential Poster: 1687 (2013) (1)
- Characterization of Mucosal Healing With Adalimumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease From EXTEND: 1611 (2014) (1)
- Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's diseaseP-39. (2011) (1)
- EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS (2021) (1)
- Tu1945 Clinical Response to Anti-MMP9 Antibody (GS-5745) is Accompanied by Histologic Improvement in Ulcerative Colitis (2016) (1)
- Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients: 792 (2005) (1)
- Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohnʼs Disease: 5-Year Results: 1821 (2015) (1)
- Mo1790 Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension (2016) (1)
- P034 EFFICACY OF USTEKINUMAB IN CROHN’S DISEASE AT MAINTENENCE WEEK 56: IM-UNITI STUDY (2019) (1)
- Sa1777 - Combined Clinical and Biological Response (Concomitant Crp and Fecal Calprotectin Reductions) in Induction and Maintenance from the Phase 3 Ustekinumab Crohn's Disease Studies (2018) (1)
- Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study (2022) (1)
- TRANSLATING MOLECULAR BIOLOGY INTO CLINICAL PRACTICE: THE ROLE OF TNF-α IN CROHN'S DISEASE (2005) (1)
- The long-term, 30-month, efficacy and tolerability of Certolizumab Pegol Therapy for Crohnʼs Disease: P-0061. (2008) (1)
- DOP062 The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy (2018) (1)
- Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel (2022) (1)
- A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. (2022) (1)
- A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study: 1841 (2015) (1)
- 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis (2019) (1)
- Dialysis of the rectum for sampling an exogenous molecule, methotrexate and an endogenous molecule, potassium: Technique and validation (1998) (1)
- P081 HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES FOR ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2019) (1)
- Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease (2011) (1)
- Immunogenicity of Natalizumab in Crohnʼs Disease Following Continuous or Interrupted Dosing: 1143 (2006) (1)
- Crohnʼs disease patients with persistently elevated CRP plasma concentration have higher rates of remission with certolizumab pegol 400 mg every 2 weeks vs every 4 weeks: P-32. (2011) (1)
- Sa1814 – Early Combined Immunosuppression is More Effective for Reducing Crohn's Disease Related Complications in Isolated Colonic Than Ileal Dominant Crohn's: Post-Hoc Analysis of React Trial (2019) (1)
- 195 HLA Class II Genotype Predicts Increased Risk for Ulcerative Colitis-Associated Colorectal Cancer and Correlates with Methylation of the MHC Class II Transactivator (Ciita) Gene (2008) (1)
- Association of Ustekinumab Concentrations Using Anser® UST Mobility Shift Assay and Clinical Response in Crohnʼs Disease: 711 (2017) (1)
- P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies (2018) (1)
- Colectomy for Ulcerative Colitis in a Large Private Insurance Claims Database: Types of Surgical and Medical Complications Occurring within 180 Days (2006) (1)
- DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis (2021) (1)
- Su2083 One-Year Response and Remission Rates in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of Ultra 2 (2012) (1)
- W1240 Adalimumab for Crohn's Disease in Clinical Practice At An Academic Medical Center: the First 118 Patients (2008) (1)
- Sa1202 Relationships Between Clinical Remission, C-Reactive Protein Normalization and Mucosal Healing in Crohn's Disease: Analyses From the SONIC trial (2013) (1)
- DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2021) (1)
- Clinical Features and Outcomes of Cytomegalovirus Colitis or Pouchitis in Patients with Inflammatory Bowel Disease: 857 (2005) (1)
- Rectal bleeding accurately reflects mucosal inflammation in patients with Ulcerative Colitis (2015) (1)
- Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii (2019) (1)
- Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. (2020) (1)
- 36 Proximal Extension of Left-Sided Ulcerative Colitis: A Population-Based Study (2008) (1)
- P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52 (2020) (1)
- P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's disease: a SONIC post hoc analysis. (2017) (1)
- Mo1218 Long-Term Outcomes of Certolizumab Pegol for Crohn's Disease: 7 Year Results From the PRECiSE 3 Study (2014) (1)
- DOP076 A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis. (2017) (1)
- The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. (2016) (1)
- Sa1266 Interferon-γ Release Assay Versus Tuberculin Skin Test in Patients With Moderate-to-Severely Active Ulcerative Colitis: Results From the PURSUIT UC Program (2015) (1)
- P378 Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study (2019) (1)
- TRANSDERMAL NICOTINE FOR ULCERATIVE COLITIS. AUTHORS' REPLY (1997) (1)
- Report from the ACG. Highlights of the 70th Annual Scientific Meeting of the American College of Gastroenterology October 28-November 2, 2005, Honolulu, HI (2006) (1)
- Once daily dosing of delayed-release oral mesalamine for maintenance of remission of Ulcerative Colitis (the QDIEM Trial): 6 and 12 month results: P-0033. (2009) (1)
- 334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis (2019) (1)
- P302 Diagnostic accuracy of a serum-based biomarker panel for endoscopic activity in ulcerative colitis (2020) (1)
- T1134 Relationship of C-Reactive Protein with Clinical Response Following Therapy with Monoclonal Antibody to IL-12/23p40 (Ustekinumab) in Crohn's Disease (2008) (1)
- Baseline C-reactive Protein (CRP) and Plasma Anti-TNF Concentration in Patients with Active Crohnʼs Disease Treated with certolizumab pegol (CZP): 1206 (2011) (1)
- Certolizumab Pegol Plasma Concentrations and Endoscopic and Clinical Outcomes in Crohnʼs Disease: A Post Hoc Analysis of the MUSIC Trial: Presidential Poster: 1667 (2012) (1)
- Efficacy of certolizumab pegol in Crohnʼs disease patients with secondary failure to infliximab is not affected by concommittant medications: P-0035. (2009) (1)
- Steroid Sparing Results in Further Improvement in Quality of Life in UC Patients in Remission: 1042 (2006) (1)
- Maintenance Therapy With Certolizumab Pegol After Induction Therapy for Active Crohn's Disease: 6-Month Results (2011) (1)
- Tu1855 EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONGTERM EXTENSION STUDY (2020) (1)
- Concomitant Use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis: P‐23 (2012) (1)
- Integrated Safety Analyses of Tofacitinib in Ulcerative Colitis Clinical Trials: 731 (2017) (1)
- Successful Use of Infliximab in the Treatment of Corticosteroid Dependent Collagenous Colitis: P‐3 YI (2012) (1)
- USE OF CROHNʼS DISEASE MEDICATIONS, INCLUDING INFLIXIMAB, ARE NOT RISK FACTORS FOR THE DEVELOPMENT OF INTESTINAL STRICTURE, STENOSIS OR OBSTRUCTION DATA FROM THE 6000-PATIENT TREAT REGISTRY: 772 (2004) (1)
- IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
- S743 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results From the UNIFI Long-Term Extension (2022) (1)
- P412 Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis (2013) (1)
- Impact of Adalimumab therapy after 12 Weeks In patients with Crohnʼs Disease who were non res ponders at week4: P-0059. (2008) (1)
- P317 Characterisation of patients with delayed response to ustekinumab for Crohn’s disease (2019) (1)
- P275 Clinical response is a meaningful endpoint in ulcerative colitis clinical studies (2013) (1)
- Pouchitis: clinical characteristics and management (2003) (1)
- Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s disease (2017) (1)
- Su1094 A Systematic Review and Meta-Analysis of Non-Invasive Biomarkers for Assessing Disease Activity in Inflammatory Bowel Disease (2015) (1)
- S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study (2021) (1)
- PTH-077 De-escalating therapy in patients with crohn’s disease receiving adalimumab: subgroup analysis of the calm study (2019) (1)
- Medical management of ulcerative colitis (2003) (1)
- Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces gut Tissue PSTAT3 in Crohn’s Disease Patients (2017) (1)
- Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease: Results of the CHARM Trial (2006) (1)
- Discordance Between Patient-Reported Outcomes and Endoscopic Inflammation in Mild-to-Moderate Ulcerative Colitis (2021) (1)
- DOP033 Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND (2014) (1)
- Su2085 Association of Baseline C-Reactive Protein With Maintenance of Remission in Anti-TNF-Experienced Patients With Moderate to Severe Crohn's Disease Treated With Adalimumab (2012) (1)
- Long-Term Safety of Certolizumab Pegol in Crohnʼs Disease: Integrated Safety Findings on Serious Adverse Events of Special Interest (2008) (1)
- Sa1734 - Impact of Prior Surgical History on Efficacy with Ustekinumab in Crohn's Disease: A Subgroup Analysis of the Phase 3 Uniti Studies (2018) (1)
- PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease (2015) (1)
- Tu1718 – Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the Im-Uniti Study (2019) (1)
- Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (1)
- P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY (2018) (1)
- Fecal Calprotectin Concentration and Clinical Remission in Patients with Active Crohnʼs Disease Treated with Certolizumab Pegol: Results from PRECiSE 1: 1175 (2011) (1)
- Sa1938 Effect of Using a Composite Endpoint on Placebo Response and Certolizumab Pegol Exposure-Efficacy Relationship: A Post-Hoc Analysis From the PRECiSE 1 and 2 Studies (2016) (1)
- T1138 Global Safety of Adalimumab in Crohn's Disease Clinical Trials (2008) (1)
- Biomarkers for assessing disease activity in inflammatory bowel disease (2013) (1)
- DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2 (2020) (1)
- Su1803 - Correlation of Endoscopic and Clinical Endpoints During Induction Therapy in Patients with Moderate to Severe Crohn's Disease: Analysis from Celest Study (2018) (1)
- Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease (2011) (1)
- P-144 Symptom Resolution and Clinical and Endoscopic Remission Both Resulted in Improved Quality of Life in Patients with Ulcerative Colitis (2013) (1)
- P245 Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis (2013) (1)
- Cost-Effectiveness of Computed Tomographic Enterography Compared to Magnetic Resonance Enterography in a Simulated Medicare Population With Crohn's Disease (2011) (1)
- Risk Factors for Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study: 1011 (2007) (1)
- Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. (2013) (1)
- P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study (2018) (1)
- P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study (2019) (1)
- 801 – Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, Pan-Jak Inhibitor Td-1473 in Moderately-To-Severely Active Ulcerative Colitis (2019) (1)
- Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE: P‐58 (2012) (1)
- Serum Albumin as a Predictor of Long-Term Response and Remission With Certolizumab Pegol for Crohn’s Disease: Results From 7-Year Data From the PRECiSE 3 Study: 1730 (2014) (1)
- 611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE (2021) (1)
- 690 Ustekinumab Maintained Clinically Meaningful Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease: Results From the IM-UNITI Long-Term Extension (2019) (1)
- Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohnʼs Disease Patients: 600 (2017) (1)
- Osteoporosis Screening in a Tertiary Referral - Inflammatory Bowel Disease: 1294 (2010) (1)
- P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy (2009) (1)
- Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II Study (2018) (1)
- Infliximab for Crohnʼs Disease: The First 262 Patients, Ten Years Later: 1252 (2009) (1)
- Su1925 Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease (2012) (1)
- 254 A Multicenter Study to Evaluate Magnetic Resonance Enterography (MRE) for Selection of Crohn's Disease Patients for Inclusion Into a Therapeutic Clinical Trial (2014) (1)
- PPAR-γ ligand antidiabetic drugs: Good news for colitis? (2000) (1)
- P243 Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease (2012) (1)
- Fistulas to the bladder and urinary tract in Crohn’s disease (2000) (1)
- Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION (2020) (1)
- Obesity Is Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort Study: 629 (2017) (1)
- Elevated C-reactive Protein in Anti-TNF-Naïve Patients is Associated with Higher Remission Rates: 1167 (2011) (1)
- Predictors of Maintenance of Long-term Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study: 1735 (2014) (1)
- Sa1192 Agreement of Central Readers in the Evaluation of Histopathological Disease Activity in Ulcerative Colitis (2014) (1)
- P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE (2013) (1)
- Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study: 850 (2005) (1)
- dvances in the Treatment of Crohn ’ s Disease (2004) (1)
- CLOSTRIDIUM DIFFICILE INFECTION IN ULCERATIVE COLITIS: 804 (2004) (0)
- First-Line and Second-Line Biologics in the Management of Moderate-Severe Crohn’s Disease: A Grade-Based Approach (2017) (0)
- Su1085 Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's Disease (2014) (0)
- Deep Remission With Vedolizumab in Patients With Ulcerative Colitis: Evaluating Various Combinations of Endoscopic and Patient-Reported Outcomes: 1629 (2014) (0)
- Letter: combination of biologics in inflammatory bowel diseases. Authors' reply (2020) (0)
- Refractory ulcerative colitis: the aggressive approach (2008) (0)
- P097 FISTULIZING CROHN’S DISEASE PREVALENCE ESTIMATE IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW AND POPULATION-BASED DATABASE ANALYSIS (2019) (0)
- Best of DDW 2004: Highlights from the 2004 Digestive Disease Week (2004) (0)
- S1202 The Effect of Time, Baseline Activity and Surgery On Crohn's Disease Activity Index (CDAI) Response Definitions to Optimize Treatment Effect Difference (2008) (0)
- Preoperative infliximab does not decrease the area of resected bowel at surgery in Crohn's disease (2003) (0)
- Sustained Remission With No Dose Escalation After Re-Induction With Certolizumab Pegol in Patients With Crohn's Disease Exacerbation Who Were NaïVE to Anti-TNF Treatment: 5-Year Results From Precise 4 (2011) (0)
- Sa1229 Durable Clinical Remission and Response in Adalimumab-Treated Patients With Ulcerative Colitis (2015) (0)
- The Classical Immunosuppression : Overrated or Underused ? Deep Remission : A New Concept ? (2013) (0)
- Efficacy of delayed-release Mesalamine 4.8g/d (800mg tablet) for treatment of moderate UC in patients with a history of difficult to treat disease: Analysis of 3 double-blind, active-controlled trials: P-0052. (2008) (0)
- Fistulas to the bladder and urinary tract in Crohn's disease (2000) (0)
- Reply: budesonide. (2013) (0)
- P286 Assessing preference for deep remission in patients with Crohn's disease (2012) (0)
- AJG-20-3412 1709..1719 (0)
- S696 Efficacy of Ustekinumab for Ulcerative Colitis in Patients Through 3 Years: UNIFI Long-term Extension (2021) (0)
- Defining Remission Using Patient-reported Outcome Components of the Crohnʼs Disease Activity Index: Post-hoc Analyses of Vedolizumab Data from the GEMINI 2 Study: 1865 (2015) (0)
- Outcomes after Acute Severe Ulcerative Colitis: Ten-Year Single-Center Experience (2008) (0)
- Su1875 – Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease (2019) (0)
- Sa1868 AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP FOR SUBCUTANEOUS VEDOLIZUMAB MAINTENANCE TREATMENT OF CROHN'S DISEASE: PHARMACOKINETIC FINDINGS FROM VISIBLE 2 (2020) (0)
- P207 One-year response and remission rates in ulcerative colitis patients with week 8 response to adalimumab: Subanalysis of ULTRA 2 (2012) (0)
- Mo1868 EFFICACY AND SAFETY OF SIMULTANEOUS TREATMENT WITH TWO BIOLOGIC MEDICATIONS IN REFRACTORY CROHN'S DISEASE (2020) (0)
- 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY (2022) (0)
- Sa467 THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD) PERFORMS BETTER THAN THE SES-CD FOR PREDICTION OF ENDOSCOPIC REMISSION IN CROHN'S DISEASE (2021) (0)
- Tu1853 SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES IL-17A AND IL-22 IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS THROUGH WEEK 52 (2020) (0)
- Preface (2010) (0)
- Infliximab Therapeutic Drug Monitoring in Clinical Practice: Indications and Utility: 1703 (2013) (0)
- Pouchitis Following Heal Pouch-Anal Anastomosis: Pathogenesis, and Treatment (1994) (0)
- Sa1816 EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 STUDY (2020) (0)
- P035 ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN’S DISEASE (2019) (0)
- The importance of early intervention and the benefit of consistent treatment in Crohn's disease therapy (2007) (0)
- Report from the ACG (2005) (0)
- P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study (2019) (0)
- Efficacy and Safety of Adalimumab in Moderate Compared with Severe Crohnʼs Disease: Pooled Data from the CHARM and EXTEND Trials: 1163 (2011) (0)
- AI-guided use of balanced peroxisome proliferator-activated receptor a/g dual agonist finetunes macrophage responses in inflammatory bowel disease (2021) (0)
- S817 The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12 (2022) (0)
- P-106 Examination of an Alternative Definition for Clinical Remission in UC: Results from TOUCHSTONE, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod (2016) (0)
- SAT0605 BODY MASS INDEX AND SYSTEMIC CORTICOSTEROID USE AS INDICATORS OF DISEASE BURDEN AND THEIR INFLUENCE ON THE SAFETY PROFILE OF CERTOLIZUMAB PEGOL ACROSS INDICATIONS (2019) (0)
- Tu1733 – Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the Touchstone Trial (2019) (0)
- P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis (2020) (0)
- 709 Optimizing the Definition of Clinical Response Using the Modified Mayo Score: An Analysis of a Phase 2 Study With Mirikizumab in Patients With Ulcerative Colitis (2019) (0)
- P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study. (2017) (0)
- Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award: 726 (2017) (0)
- Subject Index Vol. 27, Suppl. 1, 2009 (2010) (0)
- Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis (2019) (0)
- Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (2018) (0)
- T1237 Predictors of Ulcerative Colitis (UC) Relapse From a Large 12 Month Prospective Mesalamine Study (2010) (0)
- P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2 (2019) (0)
- Natural History of Patients Hospitalized with Fulminant Ulcerative Colitis: 856 (2005) (0)
- 454: OBESITY IS NOT ASSOCIATED WITH INCREASED RISK OF ADVERSE TREATMENT OUTCOMES OR SERIOUS INFECTION IN INFLAMMATORY BOWEL DISEASES PATIENTS (IBD) STARTING NEW BIOLOGIC THERAPY (2022) (0)
- Su1277 Increased Expression of T Cell Associated Genes in Baseline Biopsies From TNF Antagonist Naive Patients That Achieve Remission With Etrolizumab Treatment in a Phase II Trial in Moderate to Severely Active Ulcerative Colitis (2014) (0)
- Natalizumab Induction Therapy Results in Improved Quality of Life in Patients with Crohnʼs Disease: 1149 (2006) (0)
- A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. (2021) (0)
- DOP030 Feasibility, precision and reproducibility of MR enterography for detection of inflammation in Crohn's Disease in a multicenter clinical trial (2014) (0)
- Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply (2022) (0)
- T1217 Treatment and Prevention of Pouchitis: A Meta-Analysis of Randomized Trials (2009) (0)
- Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis: O-7. (2011) (0)
- Su1809 – A Comparision Study of Systemic Versus Targeted Intracecal Anti-TNFα Monoclonal Antibody in an Adoptive T-Cell Transfer Muine Model of Colitis (2019) (0)
- Determination of Immune Surveillance in Cerebrospinal Fluid (CSF) in Patients with Crohnʼs Disease: Initial Results of the TOSCA Study: 1748 (2013) (0)
- Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohnʼs Disease: Results From open-label extension of the CHARM trial: P-0075. (2008) (0)
- Shifts in Vedolizumab Utilization Across the United States Are Associated With Improved Outcomes (2018) (0)
- Risk Factors and Outcomes of Ischemic Colitis in a Population-based Cohort: Presidential Poster: 559 (2013) (0)
- P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease. (2017) (0)
- Adalimumab is effective for inducing clinical remission at week 4 regardless of baseline corticosteroid use (2011) (0)
- P093 IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN'S DISEASE (2020) (0)
- Association of Obesity with IBD Disease Location, Severity, and Treatment Course: A Single-Center Cohort Study (2017) (0)
- Effect of Adalimumab Dose Escalation on Hospitalization Risk in Patients With Moderately to Severely Active Ulcerative Colitis: 1808 (2015) (0)
- P-145 WELCOME 54-week Open-label Extension: Efficacy of Certolizumab Pegol in Crohn’s Disease Patients With Secondary Failure and Anti-Infliximab Antibodies: ERRATUM (2014) (0)
- What are the Causes and Treatment of Ileoanal Pouch Dysfunction (2008) (0)
- D001 PERIPHERAL EOSINOPHILS, TOTAL IGE, AND ATOPY IN NEWLY IDENTIFIED PATIENTS WITH GASTRODUODENAL EOSINOPHILIA VS CONTROLS (2021) (0)
- Adalimumab is Effective for Inducing Clinical Remission at Week 4 Regardless of Baseline Corticosteroid Use: Pooled Analysis of Four Clinical Trials: 1181 (2010) (0)
- Pouchitis and Other Pouch Dysfunction Syndromes after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study: ACG IBD Award: 1220 (2011) (0)
- Internet use by Inflammatory Bowel Disease (IBD) patients: P-0033 (2007) (0)
- Sa463 VARIATIONS IN BASELINE DISEASE CHARACTERISTICS OF PATIENTS WITH ACTIVE, MODERATE TO SEVERE CROHN'S DISEASE, BY DISEASE LOCATION (2021) (0)
- Pouchitis After Restorative Proctocolectomy (2010) (0)
- Sa576 LONG-TERM (5-YEAR) MAINTENANCE OF CLINICALLY MEANINGFUL IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE IM-UNITI LONG-TERM EXTENSION STUDY (2021) (0)
- Sa1878 POST HOC EXAMINATION OF VISIBLE 1 DATA FOR BASELINE PREDICTORS OF RESPONSE TO 2 OR 3 IV DOSES OF VEDOLIZUMAB FOR ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (2020) (0)
- Tu1712 – Reduction in Inflammatory Biomarkers in a Phase 2 Study of Mirikizumab in the Treatment of Patients with Moderatelyto-Severely Active Ulcerative Colitis (2019) (0)
- Sustained Efficacy and Tolerability of Certolizumab Pegol over 18 Months: Data from PRECiSE 2 and Its Extension Studies (PRECiSE 3 and 4): 960 (2007) (0)
- P571 Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis (2014) (0)
- Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohnʼs Disease Exacerbation: 1-Year Results from PRECiSE 4: 1171 (2011) (0)
- Pediatric “PSC-IBD”: Inflammatory bowel disease associated with primary sclerosing cholangitis in children (2000) (0)
- Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohnʼs Disease Exacerbation Who Were Naïve to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study: 1153 (2010) (0)
- Mo1220 Patient-Reported Symptom Measures Differ in Their Association With Mucosal Healing in Adults With Moderately to Severely Active Ulcerative Colitis: Results From ULTRA 1 and 2 (2014) (0)
- 129 SAFETY OF USTEKINUMAB IN IBD: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (0)
- MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease (2015) (0)
- Mo1486: MANAGEMENT OF POUCH NEOPLASIA: A CONSENSUS GUIDELINE FROM THE INTERNATIONAL ILEAL POUCH CONSORTIUM (2022) (0)
- Transient Anti-Drug Antibodies and Their Impact on Markers of Inflammation: Longitudinal Data From a 7-Year Study of Certolizumab Pegol in Crohnʼs Disease Patients: 1830 (2015) (0)
- Fecal calprotectin concentration and clinical response to certolizumab pegol in patients with active Crohnʼs disease: results from PRECiSE 2: P-42. (2011) (0)
- Inflammatory Bowel Disease in the Setting of Autoimmune Pancreatitis: 993 (2007) (0)
- Su1958 CUMULATIVE RISK OF SURGERY IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE IN POPULATION-BASED COHORTS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TIME-TREND ANALYSIS (2020) (0)
- Sa1757 - Filgotinib Decreases Systemic and Mucosal Markers of Inflammation that are Associated with Endoscopic Improvement in Moderatly to Severely Active Crohn's Disease Patients (2018) (0)
- Traitement de l'obesite et dispositif associe (2005) (0)
- Efficacy and Safety of Certolizumab Pegol in patients with active Crohnʼs Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study: P-0066. (2008) (0)
- 613 PATERNAL EXPOSURE TO IMMUNOSUPPRESSIVE AND/OR BIOLOGIC AGENTS AND BIRTH OUTCOMES IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES (0)
- Su1018: UNPLANNED HEALTHCARE UTILIZATION AND SAFETY OF BIOLOGIC THERAPY IN HISPANIC VS. NON-HISPANIC PATIENTS WITH IBD (2022) (0)
- Su1907 – Diagnostic Accuracy of the Serum-Based Mucosal Healing Index Assay in Crohn’s Disease and Comparative Accuracy to Fecal Calprotectin in Routine Practice (2019) (0)
- ALIMENTARY TRACT Lack of Effect of Intravenous Administration on Time to Respond to Azathioprine for Steroid-Treated Crohn’s Disease (1999) (0)
- Prediction of inflammatory bowel disease in patients with nonbloody diarrhea: Prospective comparison of fecal calprotectin and heme assays (1998) (0)
- Long-term Maintenance of Remission with No Dose Escalation After Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Exacerbation: 3-year Results from the PRECiSE 4 Study: 1207 (2009) (0)
- S0704 Treatment Outcome of Tofacitinib Dose Reduction to 5 mg BID vs Remaining on 10 mg BID in Patients With UC Who Were in Stable Remission on 10 mg BID: 6-Month Data From the Double-Blind, Randomized RIVETING Study (2020) (0)
- 819 - Dysregulation of the Engulfment Pathway in the Gut Epithelium Fuels Inflammatory Bowel Disease (2018) (0)
- AI-guided use of balanced PPARα/γ dual agonist finetunes macrophage responses in inflammatory bowel disease (2021) (0)
- Sa1219 Remission Rates in Crohn's Disease Patients Treated With a Re-Induction Regimen of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From the Precise 4 Study (2015) (0)
- Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. (2023) (0)
- Clinical perspectives in Crohn's disease: now and in the future. Introduction. (2007) (0)
- Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis—authors' reply (2021) (0)
- Association of Baseline C-Reactive Protein with Maintenance of Remission in Patients with Moderate to Severe Crohnʼs Disease Treated with Adalimumab: 1165 (2011) (0)
- Late Breaking Abstracts Submitted to DDW These Abstracts Were Submitted to the AGA in mid-March, Selected by the AGA Council, and Presented During DDW 2004 in New Orleans, Louisiana. (2004) (0)
- P113 EVALUATION OF THE EFFICACY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS UTILIZING THE MODIFIED MAYO SCORE: DATA FROM THE OCTAVE PROGRAM (2020) (0)
- Symptom resolution with MMX® mesalazine in patients with mild-to-moderately active ulcerative colitis who are newly diagnosed or have been living with their disease for a prolonged period (2010) (0)
- The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology: Falk Symposium 172, Miami, Fla., March 2010 (2010) (0)
- Management and Outcomes of Intra-abdominal Abscesses in Crohnʼs Disease Patients During the Anti-Tumor Necrosis Factor Era: 1247 (2009) (0)
- X. Challenges update workgroups (2008) (0)
- Report from the ACG: Highlights of the 72nd Annual Scientific Meeting of the American College of Gastroenterology, October 12-17, 2007, Philadelphia, PA (2008) (0)
- P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. (2017) (0)
- Subject Index Vol. 32, Suppl. 1, 2014 (2014) (0)
- P28 Effect of endoscopic disease criteria on endoscopic outcomes in the SEAVUE study (2022) (0)
- Tu1980 Correlation of Mucosal MMP9 Expression with Mayo Score and Endoscopic Sub-Score in Patients with Moderately to Severely Active Ulcerative Colitis (2016) (0)
- Unplanned healthcare utilization and safety of biologic therapy in Hispanic vs. non-Hispanic patients with IBD: A CA-IBD Cohort Study. (2022) (0)
- Long-term remission with certolizumab pegol in Crohnʼs disease: Efficacy over 5 years in patients with no prior anti-TNF agent exposure (precise 3 study): P36. (2011) (0)
- Global chemical effects of the microbiome include new bile-acid conjugations (2020) (0)
- Low Risk of Pneumocytis Jirovecii Pneumonia in Patients with IBD Receiving Chronic Corticosteroid Therapy Does Not Justify Prophylaxis: A Population Based Study: 1276 (2011) (0)
- A prospective, case-controlled trial of practice guidelines in inflammatory bowel disease (IBD) (2000) (0)
- REPLY FROM THE AUTHORS. (2022) (0)
- Acute pancreatitis in Crohn's disease: Clinical features and outcomes (2003) (0)
- Safety of adalimumab in global clinical trials of patients with Crohn's disease. (2011) (0)
- Low Risk of Pneumocystis Jirovecii Pneumonia in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Therapy: A Population-Based Cohort Study: 2016 ACG Fellows-In-Training Award (IBD Category): 574 (2016) (0)
- Sa1807 USTEKINUMAB MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI LONGTERM EXTENSION (2020) (0)
- Efficacy of delayed-release Mesalamine 4.8g/d (800mg tablet) for treatment of moderate UC in patients with a history of difficult to treat disease: Analysis of 3 double-blind, active-controlled trials (2011) (0)
- Different Methodologies for Determining Mayo Score in Clinical Studies Can Influence Disease Activity Assessments in Ulcerative Colitis: 1613 (2014) (0)
- Adalimumab maintains long-term remission through 2 years in patients with moderate to severe Crohnʼs Disease: P-0085. (2008) (0)
- Rate, Risk Factors and Outcomes of Recurrence of Crohnʼs Disease After Total Colectomy with Permanent Ileostomy: a Systematic Review and Meta-analysis: 656 (2016) (0)
- W1090 Prospective Observation of Quality of Life in Patients with Ulcerative Colitis Undergoing the Ileoanal Pouch Anastomosis (2009) (0)
- Burden and Costs of “High Consumers” of Hospitalization-Related Care in Patients With Chronic Gastrointestinal and Liver Diseases in the United States: 2779 (2017) (0)
- Mo1312 Cumulative Length of Bowel Resection in a Population-Based Cohort of Crohn's Disease (2013) (0)
- Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program (2022) (0)
- Immunomodulatory treatment of microscopic colitis (2000) (0)
- 684 INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL DEVELOPMENT PROGRAM: AN UPDATE AS OF MAY 2019 (2020) (0)
- The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients (2023) (0)
- T1197 Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC) (2009) (0)
- Tu1860 ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER USTEKINUMAB INDUCTION OR MAINTENANCE THERAPY WITH 2-YEAR OUTCOMES IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS (2020) (0)
- O-027: Sustainability of adalimumab in fistula healing and response: 2-year data from CHARM and an open-label extension follow-up study (2008) (0)
- 716 Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Deficiency (2014) (0)
- Exposure to Diagnostic Ionizing Radiation in a Population-Based Cohort of Patients with Inflammatory Bowel Disease: 1148 (2006) (0)
- Sa575 FILGOTINIB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: SF-36 RESULTS FROM THE PHASE 2B/3 SELECTION STUDY (2021) (0)
- MMXTM mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis: P-045. (2008) (0)
- P-152 YI Detection and Measurement of Changes in mRNA Colonic Expression of Inflammatory Genes in Biopsies from Patients with Ulcerative Colitis (2013) (0)
- Diagnostic Performance of Gastrointestinal Pathogen Panels in Patients With Suspected Infectious Gastroenteritis: A Systematic Review and Meta-Analysis: 1126 (2017) (0)
- P186 OBESITY AND RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: POOLED ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM CLINICAL TRIALS (2018) (0)
- Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY (2022) (0)
- Percutaneous injection sclerotherapy for treatment of bleeding peristomal varices: P-0001. (2008) (0)
- Inhibition of nuclear factor kappa B (NF‐kB) by aminosalicylates: Structure activity relationships (1999) (0)
- Sa1858 – Rate and Risk Factors Associated with 30- and 90-Day Readmission in Medically-Treated Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis (2019) (0)
- Safety of Delayed-Release Oral mesalamine 4.8 G/Day (800 mg Tablet) Compared to 2.4 G/Day (400 mg Tablet) for Treatment of Active Ulcerative Colitis: Combined Analysis from Three Randomized, Double-Blind, Active-Controlled Trials (2008) (0)
- BUDESONIDE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A ONE YEAR EXPERIENCE IN CLINICAL PRACTICE AT THE MAYO CLINIC (2004) (0)
- Adverse Events Related to the Use of Corticosteroids, Immunosuppressants, and Anti-TNFα Therapy in Crohnʼs Disease Patients: 1023 (2007) (0)
- P465 Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease. (2017) (0)
- Su1174 The Use of Magnetic Resonance Enterography for Diagnosis and Monitoring of Inflammatory Bowel Disease in Clinical Practice (2013) (0)
- P-122 Comparative Efficacy of Pharmacological Agents for Moderate-Severe Crohn's Disease in Patients with Prior Exposure to Anti-TNF Agents: A Network Meta-Analysis (2017) (0)
- Su1902 A SERUM BIOMARKER PANEL CAN ACCURATELY IDENTIFY THE PRESENCE OF MUCOSAL ULCERS IN PATIENTS WITH CROHN'S DISEASE (2020) (0)
- GUT-SELECTIVE BIOLOGIC THERAPY FOR ULCERATIVE COLITIS: LESSONS FROM SCIENCE AND PRACTICE (2015) (0)
- Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECiSE 2 and its extension studies (PRECiSE 3 and 4): O-028. (2008) (0)
- Sa1120 The Effect of Anti-Drug Antibodies on Adverse Events Profile in Patients With Crohn's Disease Treated With Certolizumab Pegol: Results of an Integrated Safety Analysis From Clinical Trials (2015) (0)
- O29 Efficacy and safety of mirikizumab in patients with ulcerative colitis: phase 3 LUCENT-1 study results (2022) (0)
- Anti-MAdCAM-1 therapy does not affect immune surveillance in the central nervous system (2016) (0)
- Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease (2019) (0)
- Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY (2022) (0)
- Osteonecrosis in Inflammatory Bowel Disease: Clinical Features and Outcomes (2005) (0)
- A six-month open label evaluation of CDP571, a humanized antibody to TNFa, in active Crohn's disease (2000) (0)
- Sa1265 Adalimumab Serum Concentration As a Predictor for Clinical Efficacy in Ulcerative Colitis (2015) (0)
- Intestinal lumen and tissue pharmacokinetics of methotrexate in inflammatory bowel disease: Subcutaneous methotrexate achieves pharmacologically active concentrations in the rectum (1998) (0)
- Taking a closer look at IBD (2013) (0)
- Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply (2020) (0)
- A Living Organoid Biobank of Crohn’s Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics (2023) (0)
- Budesonide Foam for Ulcerative Proctitis (UP) and Ulcerative Proctosigmoiditis (UPS): Subgroup Analyses of 2 Randomized, Placebo-Controlled, Phase 3 Studies: 1739 (2014) (0)
- Sa503 MACHINE LEARNING OUTPERFORMS TRADITIONAL RISK MODEL IN IDENTIFYING HIGH-NEED, HIGH-COST PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN A NATIONALLY REPRESENTATIVE COHORT (2021) (0)
- 968: TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTEGRATED SUMMARY OF SAFETY DATA FROM THE GLOBAL OCTAVE AND RIVETING CLINICAL TRIALS (2022) (0)
- Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 5 Years in Patients With No Prior Anti-TNF Agent Exposure (PRECiSE 3 Study) (2011) (0)
- Treat registry results: correlations between physician assessments of disease severity and IBDQ in crohn's disease patients (2000) (0)
- S0815 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease (2020) (0)
- P166 VEDOLIZUMAB MARKET ACCESS ANALYSIS OF HEALTH INSURANCE IBD POLICIES (2018) (0)
- Administration of nicotine by the colon to treat inflammatory bowel diseases. (1997) (0)
- Correction to: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (The American Journal of Gastroenterology, (2018), 113, 9, (1345-1354), 10.1038/s41395-018-0162-0) (2018) (0)
- Sa1752 - Ozanimod Induces Dose-Responsive Histological Improvement with High Agreement with Clinical Remission and Endoscopic Mucosal Healing: Results from the Touchstone Study (2018) (0)
- Mo1173 Safety Analysis of Budesonide Foam for Inducing Remission in Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Data From Two Randomized, Placebo-Controlled Trials (2014) (0)
- Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease Management in Liver Transplant Recipients: 1223 (2010) (0)
- Safety of Adalimumab in patients with Crohnʼs Disease: Analysis of global clinical trials: P-0049. (2008) (0)
- Comparison of Real World Outcomes of Adalimumab and Infliximab for Patients With Moderate or Severe Ulcerative Colitis in the United States: 1815 (2015) (0)
- Response and Remission Are Associated with Improved Quality of Life in Patients with Ulcerative Colitis: 791 (2005) (0)
- S30 A Phase 2b Study to Evaluate the Efficacy and Safety of Investigational Microbiome Therapeutic SER-287 in Mildly-to-Moderately Active UC (2022) (0)
- RETROSPECTIVE EXPERIENCE WITH CAPSULE ENDOSCOPY (CE) IN CROHNʼS DISEASE (CD): 830 (2004) (0)
- The TOSCA Study of Immune Surveillance in Cerebrospinal Fluid (CSF) in Crohnʼs Disease (CD) Patients Treated with Anti-MAdCAM Monoclonal Antibody (MAb) PF-00547659: Cohort 1 Clinical Results: 1750 (2013) (0)
- Tu1850 DOSE ESCALATION OF UPADACITINIB IN CROHN'S DISEASE PATIENTS WITH INADEQUATE RESPONSE: DATA FROM THE RANDOMISED CELEST STUDY (2020) (0)
- Clinical spectrum and outcomes in a population-based cohort with ischemic colitis (2003) (0)
- ENDOSCOPIC FACTORS IN THE DIAGNOSIS OF COLORECTAL DYSPLASIA IN CHRONIC INFLAMMATORY BOWEL DISEASE: 812 (2004) (0)
- Exploring the mechanism of action of azathioprine (AZA) in IBD: Expression profiling reveals an inhibitory effect of AZA on inflammatory cytokine gene expression in activated T cells (2003) (0)
- Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB (2021) (0)
- Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. (2022) (0)
- 886: EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDY (2022) (0)
- Sa1214 Rates of “Patient-Defined” Remission With Adalimumab in Patients With Ulcerative Colitis: Subanalysis of ULTRA 1 and ULTRA 2 (2013) (0)
- Optimal C-Reactive Protein Cutoff Point for Predicting Hospitalization in Patients With Moderately Active Crohn's Disease (2011) (0)
- Planned ileal pouch for Crohn's colitis—a reasonable approach? (2002) (0)
- Concomitant use of adalimumab and immunomodulators or corticosteroids compared with adalimumab alone (2011) (0)
- 30 Medical management of ulcerative colitis (2003) (0)
- Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease: P‐59 (2012) (0)
- Efficacy and Tolerability of Budesonide Foam With or Without Baseline 5-Aminosalicylic Acid Use in Patients With Ulcerative Proctitis (UP) or Ulcerative Proctosigmoiditis (UPS): Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies: 1732 (2014) (0)
- Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial (2017) (0)
- Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease (2021) (0)
- SHORT-TERM RESULTS: LONG-TERM (2006) (0)
- Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II) (2018) (0)
- Case report: Onset of ulcerative colitis after smoking cessation with a nicotine transdermal patch (1994) (0)
- The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECiSE 2 Trial: P‐24 (2012) (0)
- Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohnʼs disease with secondary infliximab failure: P-0030. (2009) (0)
- Benefits of Adalimumab dosage adjustment for patients with Crohnʼs Disease: An analysis of the CHARM study: P-0063. (2008) (0)
- PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study (2021) (0)
- S714 Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-Label Extension (2021) (0)
- Chapter 12. Pouchitis After Restorative Proctocolectomy (2007) (0)
- 831 Serum Biomarkers Are Associated With Endoscopic and Clinical Outcomes in Crohn’s Disease Patients Receiving Vedolizumab Therapy (2019) (0)
- Subject Index Vol. 30, Suppl. 3, 2012 (2013) (0)
- UvA-DARE ( Digital Academic Repository ) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial (2017) (0)
- Mo1214 Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension (2014) (0)
- Sa1800 EFFECT OF PATIENT-REPORTED OUTCOMES, PROMIS MEASURES AND QUALITY OF LIFE ON RISK OF HOSPITALIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY (2020) (0)
- P393 Patient-reported symptom measures differ in their association with mucosal healing in adults with moderately to severely active ulcerative colitis: Results from ULTRA 1 and 2 (2014) (0)
- Comparison of Pharmacological Therapies for Mild-Moderate Ulcerative Colitis: A Systematic Review and Network Meta-analysis: 732 (2016) (0)
- Su1221 Symptom Scores Do Not Accurately Reflect Level of Mucosal Inflammation in Patients With Crohn's Disease (2015) (0)
- クローン病におけるヒト型抗TNFモノクローナル抗体(Adalimumab):CLASSIC-1試験 (2006) (0)
- P081 Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II (2019) (0)
- 237 BASELINE DRUG CLEARANCE OF INFLIXIMAB PREDICTS COLECTOMY IN ACUTE SEVERE ULCERATIVE COLITIS (2020) (0)
- S875 The Evolution of Clinical Trial Design in Ulcerative Colitis: Interpreting Future Endpoints Based on Post-Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1 (2021) (0)
- Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis (2014) (0)
- Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease (2021) (0)
- Su1309 Terminal Ileum Intubation Is Essential for Adequate Management of Inflammatory Bowel Disease (2014) (0)
- Predictors of Hospitalization in Patients With Moderately to Severely Active Ulcerative Colitis From ULTRA 1 and ULTRA 2: 1612 (2014) (0)
- What's Hot in the Red Journal This Month (2011) (0)
- Adalimumab Therapy Reduces Hospitalization Rates in Patients With Moderate Ulcerative Colitis: 1622 (2014) (0)
- 848 Comparison of Patient Preferences Between Stool Tests and Colonoscopy for Assessment of Disease Activity in Inflammatory Bowel Diseases (2019) (0)
- A Prospectively Created Living Organoid Biobank of Crohn’s Disease Patients Enables Integrative Therapeutics (2022) (0)
- Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award (2018) (0)
- AJG-21-1127 78..97 (0)
- P117 - Global safety of adalimumab in trials of patients with Crohn's disease (2009) (0)
- Su2010 - The Anti-Madcam Antibody Shp647 in Crohn's Disease: Endoscopic Effects of Induction Therapy (2018) (0)
- W1158 Inter-Observer Agreement and Predictors of Assessment of Overall Endoscopic Severity in Ulcerative Colitis (UC) (2009) (0)
- Therapeutic advances and issues of patient adherence in the treatment of ulcerative colitis (2007) (0)
- Natalizumab Reduces the Rate of Hospitalization in Moderate to Severe Crohnʼs Patients: Data from the ENACT and ENCORE Trials: 1258 (2009) (0)
- P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial (2017) (0)
- DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial (2019) (0)
- Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohnʼs Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM: P-0117. (2009) (0)
- Su1086 Identified Areas of Need to Enhance Evidence-Based Inflammatory Bowel Disease Management and Patient Care (2014) (0)
- S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease (2022) (0)
- Adalimumab 160-/80-mg Induction Regimen is Associated With Better Outcomes Compared With the 80-/40-mg Regimen During Maintenance Therapy in Patients With Crohn's Disease (2011) (0)
- Burden, Costs and Causes for Hospitalization in Older Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort Study: 628 (2017) (0)
- VII. Report of medical therapy subcommittee (2008) (0)
- P059 MMX MESALAZINE IS AN EFFECTIVE TREATMENT FOR ACTIVE, MILD-TO-MODERATE UC REGARDLESS OF PRIOR 5-ASA USE: A POOLED ANALYSIS OF TWO PLACEBO-CONTROLLED, PHASE III TRIALS (2007) (0)
- Sa1785 - The Association of Serum 7A Hydroxy 4 Cholesten 3 One (7C4) with Bile Acid Diarrhea in Patients with Inflammatory Bowel Disease (2018) (0)
- Target Mediated Disposition (TMD) Model Based Dose Selection for Fixed SC Doses of Anti-MAdCAM-1 Monoclonal Antibody (PF-00547659) in Crohnʼs Disease: 1207 (2011) (0)
- Fr540 THE PHARMACOKINETICS AND IMMUNOGENICITY OF 5 YEARS OF TREATMENT WITH USTEKINUMAB: RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION (2021) (0)
- P033 EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY (2019) (0)
- Fr536 EARLY ONSET OF RESPONSE WITH INTRAVENOUS VEDOLIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED IN THE VISIBLE 2 STUDY (2021) (0)
- High discovery rate of duodenal and gastric eosinophilia in patients with unexplained moderate-severe abdominal symptoms: A prospective US multi-site study. (2022) (0)
- Strong Society of Abdominal Radiology Crohn ’ s Disease-Focused Panel Consensus Recommendations for Evaluation , Interpretation , and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn ’ s Disease 1 (2018) (0)
- DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study (2020) (0)
- 834 Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Analysis From a Phase 2 Study (2019) (0)
- 263 - Targeting the Stress Polarity Signaling (SPS)-Pathway Through Amp Activated Kinase: A Novel Strategy to Detect and Fix the Impaired Gut Barrier in IBD (2018) (0)
- Large Intestine Role in Maintaining Mucosal Homeostasis in the Mammalian Mediated Immune Interactions Play a Critical − Class Ib MHC (2021) (0)
- Evaluation of the Combination of Fecal Lactoferrin and Fecal Anti-Saccharomyces Cerevesiae Antibodies To Detect Active Crohnʼs Disease: 1001 (2007) (0)
- Su484 AN INTERNATIONAL CONSENSUS TOWARD STANDARDIZATION OF HISTOPATHOLOGIC SCORING FOR SMALL BOWEL STRICTURES IN CROHN'S DISEASE (2021) (0)
- Disease Location as a Risk Determinant for Maintenance of Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol: Results of Analyses From the PRECiSE 3 Study: 1733 (2014) (0)
- 619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS (2021) (0)
- ENDOSCOPIC SCORE INTER-READER CONCORDANCE ANALYSIS FROM A PHASE 2B STUDY IN PATIENTS WITH MILD-TO-MODERATE UC (2023) (0)
- Sa1241 Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis (2014) (0)
- P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study (2021) (0)
- 211 A Pilot Study of Optimized Monotherapy With Infliximab for Patients With Inflammatory Bowel Disease (2014) (0)
- P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis (2020) (0)
- P-0033: Internet use by Inflammatory Bowel Disease (IBD) patients (2007) (0)
- Mo1224 Budesonide Foam for the Treatment of Patients With Mild-to-Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Subgroup Analyses of Two Randomized, Placebo-Controlled, Phase 3 Clinical Trials (2014) (0)
- Comparison of Pharmacological Therapies for Mild-Moderate Ulcerative Colitis: A Systematic Review and Network Meta-Analysis (2017) (0)
- Tu1713 – Efficacy and Safety of 2 Or 3 Vedolizumab Intravenous Infusions As Induction Therapy for Ulcerative Colitis and Crohn's Disease: Results from Visible 1 and 2 (2019) (0)
- Abstracts (1940) (0)
- Histological Remission is Predictive of Improved Clinical Outcomes in Patients with Ulcerative Colitis: Results from the Touchstone ole (2017) (0)
- Derivation of a Microscopic Colitis Disease Activity Index (MCDAI): 1294 (2011) (0)
- The Impact of Intravenous Ketorolac (Toradol®) on the Early Recurrence of Crohnʼs Disease: 528 (2006) (0)
- S789 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease (2021) (0)
- Development of a Magnetic Resonance Imaging Index for Fistulising Crohn’s Disease Running title: MRI Index for Fistulising CD Authors: (2017) (0)
- O-0003: CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas (2008) (0)
- EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHNʼS DISEASE (ENACT-2): 788 (2004) (0)
- 209 – Early Combined Immunosuppression is Effective and Safe in Older Patients with Crohn's Disease: Post-Hoc Analysis of React Cluster Randomized Trial (2019) (0)
- Time to Remission and Response in Adalimumab-treated Patients with Moderately to Severely Active Ulcerative Colitis from ULTRA 2: 1681 (2013) (0)
- Both high-dose (4.8g/day) induction and low-dose (2.4g/day) maintenance therapy with MMXTM mesalamine have an excellent safety profile in patients with mild-to-moderate ulcerative colitis: P-028. (2008) (0)
- P-039 The Incidence of Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Anti-TNF Therapies (2017) (0)
- Sa1701 - A Multicenter Cohort Study to Assess the Safety of Vedolizumab for Inflammatory Bowel Disease (2018) (0)
- Treat registry: Examination of the long-term impact of various Crohn's disease treatment regimens (2000) (0)
- M1948 Density of Inflammatory Cell Surface Markers is Independently Associated With an Increased Risk of Colorectal Cancer in Patients With Ulcerative Colitis (2010) (0)
- Tu1749 – Pharmacokinetics and Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Ulcerative Colitis: Results from the Unifi Induction Study (2019) (0)
- Infliximab Improves Quality of Life in UC Regardless of Baseline Disease Activity: 1043 (2006) (0)
- Malignancy in Patients with Crohn's Disease: Data from the TREAT™ Registry with More Than 5 Years of Follow‐up: 1096 (2011) (0)
- Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation: 3-year results from the PRECiSE 4 study: P-0031. (2009) (0)
- DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes. (2017) (0)
- 45 – Long-Term Outcomes of In-Utero Exposure to Thiopurines and Biologic Agents in Children of IBD Mothers (2019) (0)
- Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease (2019) (0)
- Correction: Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. (2019) (0)
- Effect of HIV-2 Infection on HIV-1 Disease Progression (2012) (0)
- P093 IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN’S DISEASE (2020) (0)
- Natalizumab, Anti-II-12, Alicaforsen, Plasmapheresis, Protease Inhibitors, Phosphodiesterase Inhibitors (Future) (2006) (0)
- T1140 A Comparison of Different Definitions for Measuring the Time to Initial Symptom Resolution in Active, Mild-to-Moderate Ulcerative Colitis (2008) (0)
- Tu1927 Matrix Metalloproteinase 9 (MMP9) Expression in Ulcerative Colitis Is Associated With Histologic Score of Disease Severity (2016) (0)
- Characterization of Ulcerative Colitis Patients in the Golimumab Pursuit-Maintenance Study: Post-HOC Analyses of Patients who Maintained and did not Maintain Clinical Response Through Week 54 (2017) (0)
- Tu1268 Effect of Vedolizumab on Health-Related Quality of Life in Patients With Crohn's Disease (2015) (0)
- Rapid symptom resolution with delayed-release Mesalamine 4.8g/d compared to 2.4g/d in moderately active Ulcerative Colitis patients with a history of more difficult to treat disease: P-0032. (2009) (0)
- A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease (2021) (0)
- OC.06.1: Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in two Multinational, Phase 3 Clinical Trials (2017) (0)
- Weigh the benefits of treatment against the increase in the risk of falls when using antidepressant therapy in the elderly (2010) (0)
- DOP082 Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care (2014) (0)
- AI-guided use of balanced PPARα/g dual agonist finetunes (2021) (0)
- Co-administration of azathioprine and allopurinol in a patient with inflammatory bowel disease and gout: an indication for 6-thioguanine nucleotide montioring (2003) (0)
- S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases (2020) (0)
- S1185 Non-Fistulizing Perianal Crohn's Disease in a Population-Based Cohort (2010) (0)
- Report from the ACG: Highlights of the 71st Annual Scientific Meeting of the American College of Gastroenterology, October 20-25, Las Vegas, NV (2006) (0)
- Safety of delayed-release oral Mesalamine 4.8 g/day (800 mg tablet) for treatment of active UC: Combined analysis from 3 Randomized, double-blind, active-controlled trials: P-0062. (2008) (0)
- Su1861 – Comparative Efficacy and Speed of Onset of Infliximab Versus Golimumab in Ulcerative Colitis: A Patient-Level Analysis of Clinical Trials (2019) (0)
- 24 HIGHER BODY MASS INDEX IS ASSOCIATED WITH INCREASED RISK OF TREATMENT FAILURE AND SURGERY IN BIOLOGIC-TREATED PATIENTS WITH ULCERATIVE COLITIS (2018) (0)
- Sa1195 Patient Reported Outcome Measures Derived From the Crohn's Disease Activity Index: Correlation Between PRO2 and PRO3 Scores and CDAIDefined Clinical Thresholds (2014) (0)
- Fecal Lactoferrin (fLac) and Calprotectin (fCal) as Surrogate Markers of Mucosal Healing: Post-hoc Analysis from the PURSUIT SC Induction Study: 1864 (2015) (0)
- Benefit-Risk Assessment of Adalimumab as Maintenance Treatment for Ulcerative Colitis: NEAR Analysis of Week 8 Responders in ULTRA 2: 1593 (2012) (0)
- AJG-22-0161 1639..1647 (0)
- Tu1933 Fecal Calprotectin Improves the Predictive Power of 3 Practical Indices for Mucosal Healing Among Patients With Crohn's Disease: Results From PREDICT (2016) (0)
- MICROSCOPIC COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF COLORECTAL CANCER: 358 (2004) (0)
- Development of a Microscopic Colitis Disease Activity Index: A Prospective Cohort Study: 134 (2016) (0)
- Cost-effectiveness analysis of thiopurine methyltransferase (TPMT) screening and metabolite monitoring (MM) in the management of azathioprine (AZA)—treated Crohn's disease (CD) patients (2003) (0)
- ENACT-2 SAFETY, TOLERABILITY, AND IMMUNOGENICITY RESULTS OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE: 827 (2004) (0)
- Amelioration de traitements (2005) (0)
- Tu1732 – Changes in Simplified Endoscopic Score for Crohn's Disease (SES-CD) During a 16-Week Induction Treatment with Upadacitinib: Analysis of the Randomised Controlled Celest Study (2019) (0)
- Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation who were naïve to anti-TNF treatment: 5-year results from PRECiSE 4: P-41. (2011) (0)
- Long-term impact of Crohn's disease (CD) pharmacotherapy: Treat registry baseline results (2000) (0)
- P209 Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis (2022) (0)
- Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (0)
- 5-Aminosalicylic Acid and its major metabolite levels in patients with moderately active ulcerative Colitis following oral administration of delayed-release Mesa lamine tablets: P-0064. (2008) (0)
- Best of DDW 2008: Highlights from the 2008 Digestive Disease Week, May 17-22, 2008, San Diego, CA (2008) (0)
- Abstract 3151: A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies (2022) (0)
- P246 The association of serum 7α-hydroxy-4-cholesten-3-one (7C4) with Bile Acid Diarrhoea in patients with inflammatory bowel disease (2018) (0)
- Refining the role of TNF antagonists for Crohn's disease. Introduction. (2007) (0)
- Crohn's Disease Patients With Persistently Elevated CRP Plasma Concentration Have Higher Rates of Remission With Certolizumab Pegol 400 mg Every 2 Weeks vs. Every 4 Weeks (2011) (0)
- P056 Number Needed To Treat With MMX Mesalazine For One Patient With Mild-To-Moderate Ulcerative Colitis To Achieve Remission (2007) (0)
- Tu1467: MIRIKIZUMAB-INDUCED UPREGULATION OF COLONIC TRANSCRIPTS CORRELATES WITH IMPROVEMENTS IN STOOL FREQUENCY IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (0)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS (2019) (0)
- 644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program (2019) (0)
- P-100 Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol (2016) (0)
- DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease (2018) (0)
- Su2078 Concomitant use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis (2012) (0)
- Abstracts (2005) (0)
- Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction: 1700 (2014) (0)
- Herbal Extract Hpml-004 in Active Ulcerative Colitis: a Randomized Comparison with Sustained Release mesalamine (2008) (0)
- Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis: 1858 (2015) (0)
- Sa1880 DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA (2020) (0)
- Azathioprine downregulates trail expression in a T cell line and in normal human peripheral blood T cells (2003) (0)
- Centrally-Determined Standardization of Flow Cytometry Methods Reduces Inter-Laboratory Variation in a Prospective Multicenter Study (2017) (0)
- Su1886 - Burden of Hospitalization and Predictors of High Healthcare Utilization in Patients with Inflammatory Bowel Diseases in the United States (2018) (0)
- P-137 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
- Thiopurine methyltransferase in the jejunum Cellular localization and correlation with red blood cell TPMT (2000) (0)
- Mo1296 Quality of Life for Patients With Deep Remission vs. Clinical Remission and Deep Remission vs. Absence of Mucosal Ulceration: 3-Year Data From CHARM/ADHERE (2013) (0)
- Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12 (2022) (0)
- S786 Psychometric Evaluation of PROMIS-Fatigue Short Form Scales in Patients With Moderately to Severely Active Crohn’s Disease (2021) (0)
- Sa1889 PATIENTS WITH CROHN'S DISEASE AT RISK OF SUBTHERAPEUTIC CERTOLIZUMAB PEGOL DRUG EXPOSURE CAN BE IDENTIFIED PRIOR TO INITIATION OF THERAPY (2020) (0)
- MMX mesalamine, a novel formulation, effectively induces remission of mild-tomoderate ulcerative colitis: a pooled analysis of two phase III studies: P-0079. (2007) (0)
- S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study (2021) (0)
- Highlights from the 2003 digestive disease week. Best of DDW 2003 (2003) (0)
- Design of clinical trials for mild-to-moderate Crohn's disease. (2022) (0)
- Incidence, Risk Factors, and Outcome of Advanced Neoplasia in Patients Ulcerative Colitis with Low-Grade Dysplasia: A Systematic Review and Meta-analysis: 657 (2016) (0)
- Adalimumab Therapy maintains remission for up to 3 Years in patients with moderately to severely active Crohnʼs Disease: Results From an Open-Label Extension of CHARM: P-0121. (2009) (0)
- Biologic Concentration Testing in Inflammatory Bowel Disease how this access benefits you. Your story matters (0)
- W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease (2009) (0)
- Su1913 MAGNITUDE OF INCREMENTAL BENEFIT OF ACHIEVING DEEPER ENDOSCOPIC AND HISTOLOGIC TREATMENT TARGETS IN PATIENTS WITH ULCERATIVE COLITIS IN STRIDE-DEFINED REMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
- P012 CERTOLIZUMAB PEGOL LONG-TERM SAFETY ADJUSTED FOR DURATION OF EXPOSURE: NOVEL DATA FROM THE DEVELOPMENT PROGRAMME (2008) (0)
- Baseline C-Reactive Protein is Associated With Disease Progression in Patients with Crohnʼs Disease: 1164 (2011) (0)
- Best of ACG 2008 (2008) (0)
- Colorectal cancer and dysplasia in inflammatory bowel disease : a review of disease epidemiology , pathophysiology , and management Running Title : Colorectal Cancer in Inflammatory Bowel Disease (2016) (0)
- P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy (2019) (0)
- Certolizumab pegol efficacy is greater with more recent-onset Crohnʼs Disease: PRECiSE 2 results: P-0080. (2007) (0)
- P026 SAFETY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: A META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS (2008) (0)
- Colectomy for Ulcerative Colitis in a Large Private Insurance Claims Database: Types of Colectomy and Associated Follow-Up Surgical Procedures (2006) (0)
- 642 Effects of Ustekinumab Maintenance Therapy on Endoscopic Improvement and Histologic Improvement in the UNIFI Phase 3 Study in Ulcerative Colitis (2019) (0)
- S716 Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study (2022) (0)
- Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. (2019) (0)
- Anti-TNF Alpha Drug Induced Pustular Psoriasis-A Paradoxical Reaction (2009) (0)
- Tu1854 MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF RESISTANCE AND ULCERATIVE COLITIS DISEASE ACTIVITY (2020) (0)
- 971 Perioperative Anti-Tumor Necrosis Factor Alpha Agnents Do Not Increase the Rate of Early Postoperative Complications in Crohn's Disease (2010) (0)
- PD-009 A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC (2017) (0)
- Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease (2021) (0)
- S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12 (2022) (0)
- P-138 Sustained Efficacy in Patients with Ulcerative Colitis Treated with Adalimumab: Results from ULTRA 2 (2013) (0)
- Sa1729 - Comparison of Gastrointestinal Pathogen Panel and Conventional Stool Evaluation for Evaluation of Diarrhea in Inflammatory Bowel Disease (2018) (0)
- Efficacy of Adalimumab for the Treatment of TNF-Antagonist-Naïve Patients with Crohnʼs Disease: Subanalysis of a Phase III Trial (2008) (0)
- Systematic Review: Safety and Diagnostic Impact of Double-Balloon Enteroscopy in Crohnʼs Disease: Presidential Poster: 1471 (2015) (0)
- 715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program (2019) (0)
- P066 Analysis of the Effect of Induction Response on the Response and Remission at 18 Months of Certolizumab Pegol in Crohn's Disease: Data from Precise 2 and 3 (2008) (0)
- Sa1200 Presence and Concentration of OmpC As a Risk Factor for Developing Antibodies to Infliximab (ATI): Implications for Selecting Patients With Inflammatory Bowel Disease (IBD) for Combination Therapy (2014) (0)
- 13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab (2009) (0)
- A Novel Galacto-Oligosaccharide (RP-G28) Promotes Beneficial Adaptations to the Human Gut Microbiome in Patients With Lactose Intolerance (2018) (0)
- CLINICAL—ALIMENTARY TRACT Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis (2009) (0)
- P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib (2020) (0)
- Infliximab Therapy Reduces Hospitalizations in Ulcerative Colitis Patients: 847 (2005) (0)
- Sa1213 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
- Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: 1614 (2012) (0)
- diagnosis and management of Crohn's disease European evidence-based consensus on the (2007) (0)
- P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease (2019) (0)
- Operating Properties of Different Patient Reported Outcome Endpoints Combined With Endoscopic Evaluation: Data From EXTEND: 2259 (2015) (0)
- S0768 Early and Durable Symptom Control in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod (APD334) in the Phase 2 OASIS Trial and Open Label Extension (2020) (0)
- Delivering nicotine in the large intestine for the treatment of inflammatory bowel diseases (1997) (0)
- The Safety Profile of Biologic Therapy in Older IBD Patients - A Pilot Study: 1242 (2009) (0)
- Induction of remission with extended MMXTM mesalamine therapy: time to resolution of UC symptoms: P-0026. (2008) (0)
- A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease (2021) (0)
- Adalimumab Induced and Maintained Clinical Remission in Patients with Crohnʼs Disease Independent of Baseline CRP Concentration: Subanalysis of the CHARM Study (2006) (0)
- P378 Safety of adalimumab in global clinical trials of ulcerative colitis patients (2013) (0)
- Hospitalization Rates in Patients with Crohnʼs Disease and Deep Remission: Data from the 56-week CHARM Trial: 1813 (2013) (0)
- Clinical Benefit of Adalimumab Dose Adjustment for Patients With Moderately to Severely Active Crohn’s Disease in EXTEND: 1610 (2014) (0)
- W1331 Effect of Itraconazole on Inflammatory Bowel Disease Activity in Patients Treated for Histoplasmosis (2010) (0)
- Su1901 DIAGNOSTIC ACCURACY OF A SERUM-BASED BIOMARKER PANEL FOR ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS (2020) (0)
- P030 Continuous Adalimumab Maintenance Therapy Yields Better Outcomes than Induction and Reinitiated Therapy for Moderate to Severe Crohn's Disease: Subanalysis of Charm (2008) (0)
- Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? (2020) (0)
- P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54. (2017) (0)
- Vedolizumab Results in Durable Clinical Remission in Crohn’s Disease: 1614 (2014) (0)
- farmnaceutica composition for the treatment of intestinal disease inflmatoria. (1998) (0)
- Comprar The Keys To Ibd 2010: Treatment, Diagnosis And Pathophysiology | Rogler, G. | 9783805595889 | Karger AG (2010) (0)
- S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study (2022) (0)
- A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN’S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY (2018) (0)
- Infliximab for ulcerative colitis - Reply (2006) (0)
- Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis: Data From Controlled Trials: 1203 (2011) (0)
- DOP059 Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's disease (2014) (0)
- 851 Targeted Intracecal anti-α4β7 Integrin Antibody Results in Reduce Accumulation of α4β7 Memory T-cells in Gut Tissue in DSS-induced Colitis Mice (2019) (0)
- Concomitant Use of Adalimumab and Immunomodulators or Corticosteroids Compared with Adalimumab Alone: Pooled Safety Analysis: 2010 Presidential Poster: 1141 (2010) (0)
- Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study (2020) (0)
- S0662 Evaluating the Optimum Number of Biopsies to Assess Histologic Inflammation in Ulcerative Colitis (2020) (0)
- EFFICACY AND SAFETY OF ASACOL 4.8G/DAY (800 MG TABLET) COMPARED TO 2.4 G/DAY (400 MG TABLET) IN TREATING MODERATELY ACTIVE ULCERATIVE COLITIS: 775 (2004) (0)
- KEEP CALM AND TREAT TO TARGET IN INFLAMMATORY BOWEL DISEASE This symposium took place on 30 th October 2017 , as part of the 25 th United European Gastroenterology ( UEG ) Week in Barcelona , Spain (2017) (0)
- Mo1824 – Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2019) (0)
- Can immunomodulatory therapy be improved by metabolite measurement and combination therapy (2007) (0)
- Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA (2020) (0)
- DOP031 A multicenter study to evaluate magnetic resonance enterography (MRE) for selection of Crohn's disease patients for inclusion into a therapeutic clinical trial (2014) (0)
- 697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis (2019) (0)
- S1405 Endoscopy and Systematic Biopsy of Patients With Moderate-Severe Unexplained Gastrointestinal Symptoms Compared With Healthy Controls: High Discovery Rate of Eosinophilic Gastritis and/or Eosinophilic Duodenitis (2021) (0)
- An expert consensus to standardize definitions , diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn ’ s disease SHORT TITLE : Novel anti-fibrotics for Crohn ’ s disease (2018) (0)
- University of Birmingham Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's Disease (2018) (0)
- Tu1728 – Long-Term Efficacy and Pharmacodynamics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1) Monoclonal Antibody Shp647 in Crohn's Disease: the Opera Ii Study (2019) (0)
- P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis (2019) (0)
- Outcomes in Women With Inflammatory Bowel Disease : Large Community-Based Study From Northern California (2007) (0)
- DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis (2019) (0)
- Early combined immunosuppression reduces complications in long-standing Crohn's disease: a post hoc analysis of REACT. (2020) (0)
- Clinical remission as defined by the Mayo Score: do we deceive ourselves? (2015) (0)
- MR Enterography for Crohn's Disease: Performance Assessment in a Large Abdominal Imaging Practice (2011) (0)
- P-0034: Rapid improvement of patient-reported CDAI diary components by day 8 in active Crohn's disease patients treated with certolizumab pegol (2009) (0)
- P738 Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters (2018) (0)
- Class Ib MHC–Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine (2021) (0)
- Satisfaction with therapy among patients treated with MMXTM mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis: P-044. (2008) (0)
- 770 Relationship Between Protocol Specified Corticosteroid Tapering Regimens and Achieving Outcome Measures in Patients With Moderate-Severe Ulcerative Colitis and Crohn's Disease (2019) (0)
- Three strikes and you're out—interleukin‐10 in Crohn's disease (2002) (0)
- CLINICAL—ALIMENTARY TRACT Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis (2010) (0)
- Sa1772 - Sustained Clinical Remission with Vedolizumab in Moderateto-Severe Crohn's Disease: A Gemini 2 Post HOC Analysis of Week 14 Remitters (2018) (0)
- DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study (2021) (0)
- Crohn's disease. Edited by C. Prantera and B. I. Korelitz. 591 pp. Monticello, NY: Marcel Dekker, 1996. $150.00 (1997) (0)
- First-Line and Second-Line Biologic Agents and Small Molecules in the Management of Moderate-Severe Ulcerative Colitis: A Grade-Based Approach (2017) (0)
- P154 PRIMARY NON-RESPONSE TO TUMOR NECROSIS FACTOR ANTAGONISTS IS ASSOCIATED WITH INFERIOR RESPONSE TO SECOND-LINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS (2018) (0)
- Crohn's disease: Playing by new rules (2003) (0)
- A pharmaceutical composition for the treatment of inflammatory bowel disease (1998) (0)
- P017 Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Colectomy Analysis from ACT1 and ACT2 (2008) (0)
- Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naïve to anti-TNF treatment (2011) (0)
- Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohnʼs Disease Patients: Results from the IM-UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663 (2016) (0)
- 473 - Impact of Continuing 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data from Infliximab and Golimumab Clinical Trials (2018) (0)
- Early Endoscopic Evaluation After Initiation of Biologic Therapy Reduces Disease-Related Complications in Inflammatory Bowel Disease, Supporting the Concept of Treat-to-Target (2018) (0)
- Tu1447: IZENCITINIB INDUCTION TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (2022) (0)
- P-0019: Long-Term safety of Certolizumab Pegol in Crohn's Disease: Integrated safety findings on serious adverse events of special interest (2008) (0)
- Tu1719 – Clinical Remission by Legacy Versus Fda Definitions: Definition Justification and Results from Unifi Study (2019) (0)
- Reply: To PMID 24036054. (2015) (0)
- The Association of Serologic Inflammatory Markers with Microscopic Colitis Disease Activity: 420 (2011) (0)
- DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study (2021) (0)
- Anti-TNF Alpha Drug Induced Pustular Psoriasis - A Paradoxical Reaction: 961 (2009) (0)
- E22 Why failure of medical treatment (clinical aspects) (2010) (0)
- Long-Term Consequences of Surgery in Patients With Ulcerative Colitis: A Study Using German Claims Data (2021) (0)
- Prevalence of extraintestinal manifestations and autoimmune disorders in patients with familial and sporadic inflammatory bowel diseasehten (2000) (0)
- Chapter 6. Clinical Trials (2008) (0)
- Ultrasound Guided Percutaneous Injection Sclerotherapy for Treatment of Bleeding Peristomal Varices: 820 (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William Jeffery Sandborn?
William Jeffery Sandborn is affiliated with the following schools:
